<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Immunol Immunother</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Immunol. Immunother</journal-id><journal-title-group><journal-title>Cancer Immunology, Immunotherapy</journal-title></journal-title-group><issn pub-type="ppub">0340-7004</issn><issn pub-type="epub">1432-0851</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5626801</article-id><article-id pub-id-type="publisher-id">2025</article-id><article-id pub-id-type="doi">10.1007/s00262-017-2025-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Hamid</surname><given-names>Omid</given-names></name><address><phone>310-294-0438</phone><email>ohamid@theangelesclinic.org</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hoffner</surname><given-names>Brianna</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gasal</surname><given-names>Eduard</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hong</surname><given-names>Jenny</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Carvajal</surname><given-names>Richard D.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label>The Angeles Clinic and Research Institute, 11818 Wilshire Blvd #200, Los Angeles, CA 90025 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9908 7089</institution-id><institution-id institution-id-type="GRID">grid.413085.b</institution-id><institution>University of Colorado Hospital, </institution></institution-wrap>Aurora, CO USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0657 5612</institution-id><institution-id institution-id-type="GRID">grid.417886.4</institution-id><institution>Amgen Inc., </institution></institution-wrap>Thousand Oaks, CA USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2152 9905</institution-id><institution-id institution-id-type="GRID">grid.50956.3f</institution-id><institution>Cedars-Sinai Medical Center, </institution></institution-wrap>Los Angeles, CA USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2285 2675</institution-id><institution-id institution-id-type="GRID">grid.239585.0</institution-id><institution>Columbia University Medical Center, </institution></institution-wrap>New York, NY USA </aff></contrib-group><pub-date pub-type="epub"><day>15</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>66</volume><issue>10</issue><fpage>1249</fpage><lpage>1264</lpage><history><date date-type="received"><day>18</day><month>10</month><year>2016</year></date><date date-type="accepted"><day>23</day><month>5</month><year>2017</year></date></history><permissions><copyright-statement>&#169; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Oncolytic immunotherapy is a research area of cancer immunotherapy investigating the use of modified viruses to target cancer cells. A variety of different viral backbones (e.g., adenovirus, reovirus) with a diverse range of genetic modifications are currently being investigated for the treatment of a variety of cancers. The oncolytic virus that has advanced the furthest in clinical development is talimogene laherparepvec, a recombinant HSV-1 virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF). In a phase 3 study in patients with unresectable metastatic melanoma, intralesional talimogene laherparepvec treatment resulted in a higher durable response rate compared with subcutaneous GM-CSF treatment (16.3 versus 2.1%; <italic>P</italic>&#160;&lt;&#160;0.001). Notably, responses were observed at uninjected lesions including visceral lesions, indicating a systemic antitumor response had occurred. Studies evaluating combination treatments involving oncolytic viruses and immunologic agents are ongoing. This review focuses on the mechanisms of action for oncolytic viruses and highlights select agents and combinations currently in development.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Oncolytic immunotherapy</kwd><kwd>Talimogene laherparepvec</kwd><kwd>Immunotherapy</kwd><kwd>Melanoma</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100002429</institution-id><institution>Amgen</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par12">Oncolytic immunotherapy is an area of research that investigates the use of modified viruses to induce a systemic immune response to target cancer cells. This represents a novel approach to anticancer therapy; however, the potential for viruses to induce an antitumor immune response has been known for some time. The earliest clinical references to oncolytic viruses were case reports in the early 1900s, primarily describing the remission of malignancies, usually leukemias or lymphomas, after viral infections or live-virus vaccinations [<xref ref-type="bibr" rid="CR1">1</xref>] (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). The first documented case of viral infection&#8211;induced regression was in 1904 in a patient with chronic myelogenous leukemia [<xref ref-type="bibr" rid="CR2">2</xref>]. The patient experienced a marked reduction in white blood cells during a &#8220;flu-like&#8221; illness. Additional evidence consistent with an ability of viruses to induce an antitumor response was reported over a long period of time. These findings were with a variety of different tumor types (including leukemia, cervical cancer, lymphomas, solid tumors, melanoma, and multiple myeloma) and viruses (including rabies virus, mumps virus, measles virus, adenovirus, parvovirus, and Newcastle disease virus) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>&#8211;<xref ref-type="bibr" rid="CR9">9</xref>]. Together, these observations led to the hypothesis that viruses, and in particular genetically engineered viruses, are immunogenic and might be employed in the treatment of cancer.<fig id="Fig1"><label>Fig.&#160;1</label><caption><p>History of oncolytic viruses. <italic>GM</italic>-<italic>CSF</italic> granulocyte-macrophage colony-stimulating factor, <italic>HNC</italic> head and neck cancer, <italic>HSV</italic>-<italic>1</italic> herpes simplex virus type 1, <italic>NDV</italic> Newcastle disease virus, <italic>T</italic>-<italic>VEC</italic> talimogene laherparepvec</p></caption><graphic xlink:href="262_2017_2025_Fig1_HTML" id="MO1"/></fig>
</p><p id="Par13">Oncolytic immunotherapy employs viruses to directly lyse cancer cells (oncolysis). These viruses infect tumor cells, where they undergo a series of replication cycles and are subsequently released through cell lysis to infect adjacent cancer cells. This cycle can repeat hundreds of times, attacking and decreasing the tumor cell mass [<xref ref-type="bibr" rid="CR1">1</xref>]. Oncolysis also results in the release of tumor-derived antigens that can stimulate a local and systemic antitumor immune response; thus oncolytic therapy can represent an immunotherapeutic approach by which a patient&#8217;s own immune system can combat tumor growth and promote tumor removal [<xref ref-type="bibr" rid="CR1">1</xref>] (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Through the availability of new recombinant DNA technology, oncolytic viruses can be genetically engineered for enhanced activity compared with wild-type viruses. For example, oncolytic viruses can be genetically modified for tumor-selective replication; thus these agents spare neighboring noncancerous tissue while killing targeted cancer cells through lysis. Alternatively, such techniques can also be used to select the most active wild-type viruses for therapeutic use [<xref ref-type="bibr" rid="CR10">10</xref>].<fig id="Fig2"><label>Fig.&#160;2</label><caption><p>Viral oncolysis mechanism of action and immunogenic response to viral infection. Lysis of tumor cells following viral replication results in release of tumor-derived antigens (TDA), which promote the activity of the cancer-immunity cycle, ultimately resulting in the development of a tumor-specific immune response. <italic>APC</italic> antigen-presenting cells</p></caption><graphic xlink:href="262_2017_2025_Fig2_HTML" id="MO2"/></fig>
</p><p id="Par14">The goal of this review is to highlight the recently approved oncolytic immunotherapy talimogene laherparepvec, and to describe other oncolytic immunotherapies that are currently in development. The review focuses on the mechanisms of action for engineered oncolytic immunotherapies, important considerations for the clinical development of these agents, current trials under investigation, possible future developments as combinatorial therapies, and the side-effect profiles of oncolytic immunotherapies (which differ from other treatment modalities such as chemotherapy [<xref ref-type="bibr" rid="CR11">11</xref>]).</p></sec><sec id="Sec2"><title>Suggested mechanism of action</title><p id="Par15">Oncolytic viruses can kill cancer cells through a number of mechanisms [<xref ref-type="bibr" rid="CR12">12</xref>], including (1) direct oncolysis or apoptosis of infected cells [<xref ref-type="bibr" rid="CR13">13</xref>], (2) apoptotic death of uninfected cells [<xref ref-type="bibr" rid="CR14">14</xref>], and (3) induction of an immune response [<xref ref-type="bibr" rid="CR15">15</xref>]. With direct oncolysis, the virus causes lysis or apoptosis of a host cell as a direct result of replication or infection. With replication, the lytic cycle is recapitulated as the viral particles are released and infect neighboring cells [<xref ref-type="bibr" rid="CR13">13</xref>]. Through this method, the viral load continues to increase until attenuated by an immune response or depletion of susceptible host cells.</p><p id="Par16">Apoptosis is a defense mechanism employed by infected hosts to limit viral spread by eliminating the cellular machinery necessary for viral replication [<xref ref-type="bibr" rid="CR14">14</xref>]. Oncolytic viruses have been found to be able to trigger apoptosis in neighboring, uninfected cancer tissue [<xref ref-type="bibr" rid="CR14">14</xref>]. The exact mechanism by which apoptosis is triggered in uninfected cells has yet to be fully elucidated, but theories include transfer of empty virion capsids [<xref ref-type="bibr" rid="CR16">16</xref>] or binding of viral proteins to extracellular receptors, triggering apoptosis through caspase-mediated mechanisms [<xref ref-type="bibr" rid="CR17">17</xref>]. Many tumor cells contain defects in the apoptotic pathway (e.g., mutated p53) that allow for tumor growth but usually retain the ability to execute the apoptosis cascade when initiated. Most chemotherapies are unable to trigger this mechanism in p53-deficient tumors because functional p53 is required [<xref ref-type="bibr" rid="CR18">18</xref>]; however, some oncolytic viruses are designed to circumvent this restriction to trigger apoptosis in cancer cells [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Deletion of the viral protein E1, a known inhibitor of apoptosis, allows for an increase in p53 levels leading to apoptosis. Furthermore, some viral proteins are known to induce apoptosis in tumor cells [<xref ref-type="bibr" rid="CR20">20</xref>]. Certain oncolytic viruses (e.g., vaccinia virus) can also be designed to kill tumor cells by targeting vascular development (angiogenesis), leading to noninfected tumor cell death [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. In this instance, infection by an oncolytic virus disrupts tumor vasculature, decreasing blood flow to tumor cells, leading to tumor hypoxia [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Widespread tumor cell infection and/or necrosis follow these effects at later time points [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par17">Tumor cells can also be killed via induction of an immune response [<xref ref-type="bibr" rid="CR15">15</xref>]. Infected tumor cells are highly immunogenic; the production of cytokines and chemokines and release of tumor-derived antigens from lysed tumor cells can induce a tumor-specific immune response, potentially resulting in the elimination of uninfected cancer cells [<xref ref-type="bibr" rid="CR15">15</xref>]. Furthermore, a systemic immune response could potentially induce a response at distant uninjected lesions. The potential for oncolytic viruses to induce a tumor-specific immune response has led to the engineering and clinical testing of oncolytic viruses designed to enhance this response, in particular through insertion of genes that encode cytokines [e.g., granulocyte-macrophage colony-stimulating factor (GM-CSF) [<xref ref-type="bibr" rid="CR23">23</xref>&#8211;<xref ref-type="bibr" rid="CR26">26</xref>], Flt3L [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]] or chemokines (e.g., CCL3 [<xref ref-type="bibr" rid="CR27">27</xref>], CCL5 [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]).</p></sec><sec id="Sec3"><title>Genetic modification of oncolytic viruses</title><p id="Par18">A number of genetically engineered viruses have been created to target specific tissues or tumor types [<xref ref-type="bibr" rid="CR31">31</xref>] and are being evaluated in clinical trials [<xref ref-type="bibr" rid="CR32">32</xref>] (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Engineered viral backbones under clinical investigation include herpes simplex virus type 1 (HSV-1), adenovirus, coxsackievirus A21, reovirus, vaccinia virus, vesiculostomatitis virus, and poliovirus. Recently, the first oncolytic immunotherapy (talimogene laherparepvec; IMLYGIC<sup>&#8482;</sup>) was approved by the United States Food and Drug Administration, the European Medicines Agency, and the Australian Therapeutic Goods Administration for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma [<xref ref-type="bibr" rid="CR33">33</xref>&#8211;<xref ref-type="bibr" rid="CR35">35</xref>].<table-wrap id="Tab1"><label>Table&#160;1</label><caption><p>Select oncolytic viruses in development</p></caption><table-wrap-foot><p>
<italic>CNS</italic> central nervous system, <italic>GIST</italic> gastrointestinal stromal tumor, <italic>GM-CSF</italic> granulocyte-macrophage colony-stimulating factor, <italic>HNSCC</italic> head and neck squamous cell carcinoma, <italic>HSV-1</italic> herpes simplex virus type 1, <italic>IFN</italic> interferon, <italic>IL-15</italic> interleukin-15, <italic>IRES</italic> internal ribosome entry site, <italic>MAGE-A3</italic> melanoma antigen family A3, <italic>NSCLC</italic> non&#8211;small-cell lung cancer, <italic>SCLC</italic> small-cell lung cancer</p><p>
<sup>a</sup>Clinical trial data available from <ext-link ext-link-type="uri" xlink:href="http://www.ClinicalTrials.gov">www.ClinicalTrials.gov</ext-link>; ongoing trials are in bold</p></table-wrap-foot></table-wrap>
</p><p id="Par19">Various approaches have been used to enhance the antitumor activity and tumor selectivity of oncolytic viruses [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Modifications may be introduced to influence a number of aspects of the viral mechanism of action. Enhanced tumor selectivity can be achieved by either deleting genes critical for viral replication in healthy cells or by placing tumor-specific promoters of mRNA transcription upstream of those critical genes [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Additionally, because mutations in the tumor suppressor genes <italic>p53</italic> and <italic>pRb</italic> result in a loss of cell cycle control in tumor cells, some oncolytic viruses have been engineered to take advantage of this loss of growth control. Engineered viruses containing deletions in genes involved in the inhibition of apoptotic cell death undergo markedly less viral replication in noncancerous cells as compared with tumor cells [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. For example, an adenovirus with the viral protein E1B55kd deleted (ONYX-015) showed tumor-selective replication that was originally thought to be related to the inability of the mutant protein to degrade p53 [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. However, more recent data showed that the replication selectivity for tumor cells occurs mainly via an increase in the export and expression of late viral RNAs, which are required for the production of infectious virions [<xref ref-type="bibr" rid="CR36">36</xref>].</p><p id="Par20">In addition, virulence factors that are important for downregulating the host antiviral response can be deleted to selectively allow replication in tumor cells while sparing normal cells. In the laboratory setting, virulence factor gene deletion has been shown to allow for replication in actively dividing cells (e.g., tumor cells), while reducing proliferation in normal cells [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. For instance, deletion of the <italic>ICP34.5</italic> gene in HSV-1 attenuated neurovirulence because inhibition of the gene product disables the capacity of the virus to replicate in the central nervous system [<xref ref-type="bibr" rid="CR38">38</xref>].</p><p id="Par21">Another strategy employs tumor-specific or tissue-specific promoters of transcription to regulate tumor selectivity; the virus is only able to replicate in cells in which the specific promoter is active [<xref ref-type="bibr" rid="CR13">13</xref>]. Integrating tissue-specific promoters (e.g., osteocalcin promoter) or tumor-specific antigen promoters (e.g., prostate-specific antigen promoter) upstream of viral genes necessary for replication can ensure that proliferation becomes dependent on characteristics unique to tumor cells [<xref ref-type="bibr" rid="CR32">32</xref>]. The proof of this concept was demonstrated in a 1999 study in which an adenovirus was placed under the control of the &#945;-fetoprotein (AFP) gene promoter and shown to replicate in a hepatocellular carcinoma cell line expressing AFP but not in normal human cells [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par22">Lastly, antitumor potency may be enhanced through gene insertion; virus-inducing tumor cell lysis can be augmented by inserting viral genes that encode toxic proteins such as adenoviral death protein or syncytium induction [<xref ref-type="bibr" rid="CR32">32</xref>]. Furthermore, a local and systemic immune response may be enhanced through the insertion of immune-activating cytokine genes such as human GM-CSF that potentially increase local cytokine expression and tumor-infiltrating lymphocytes. Such genetic modifications can induce inflammation, increase expression of major histocompatibility complex molecules, and activate antigen-presenting dendritic cells, effectively inducing a systemic immune response [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>].</p></sec><sec id="Sec4"><title>Clinical development considerations for oncolytic immunotherapies</title><p id="Par23">Because introduction of an oncolytic virus elicits an immune response, macrophage infiltration and inflammation can increase tumor dimensions (i.e., pseudoprogression) before clinical improvements are seen [<xref ref-type="bibr" rid="CR42">42</xref>]. Pseudoprogression has been reported to occur with many immunotherapies, consequently, optimal use of such therapies may require continued therapy past the initial increase in tumor lesion size, with tumor responses observed following initial growth on treatment [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR43">43</xref>&#8211;<xref ref-type="bibr" rid="CR45">45</xref>]. A study presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting found that in 356 patients with advanced solid tumors treated with anti-PD1, anti-PD-L1, or anti-CTLA-4 antibodies alone or in combination with VEGF or BRAF (V600E) inhibitors, pseudoprogression per immune-related response criteria (irRC) occurred in 21 patients (6%) [<xref ref-type="bibr" rid="CR46">46</xref>]. Of these 21 patients, 17 (81%) were alive at 1&#160;year [<xref ref-type="bibr" rid="CR46">46</xref>]. Pseudoprogression has also been reported to occur with oncolytic immunotherapy [<xref ref-type="bibr" rid="CR47">47</xref>]. Furthermore, even with disease progression following an initial response to therapy, immune responses can be reintroduced with retreatment, effectively eliciting complete and partial responses (PRs) as well as stable disease [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</p><p id="Par24">Because they have a mechanism of action that differs from other available cancer therapies, oncolytic immunotherapies are anticipated to have potential toxicities that differ from these agents. Adverse events most commonly reported with oncolytic viruses include chills, pyrexia, and influenza-like illness [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Because oncolytic immunotherapies employ live viruses, they may cause serious infections in patients who are immunocompromised; therefore patients who are receiving immunosuppressive therapy should not receive additional treatment with oncolytic immunotherapies [<xref ref-type="bibr" rid="CR33">33</xref>]. Furthermore, careful consideration should be given before administering oncolytic viruses to patients who are receiving antiviral medications as these agents may interfere with the effectiveness of oncolytic therapy [<xref ref-type="bibr" rid="CR33">33</xref>]. Other potential concerns include natural predisposition toward genomic alterations (i.e., mutations), replication competence (e.g., self-propagation), host-cell selectivity (e.g., tumor specificity), viral shedding, and secondary transmission (e.g., infection of close contacts) [<xref ref-type="bibr" rid="CR51">51</xref>]. However, these potential concerns have not proven to be of significant concern in clinical studies [<xref ref-type="bibr" rid="CR52">52</xref>]. No data are available for patients with immune deficiency as clinical trials with oncolytic immunotherapies normally exclude these populations.</p><p id="Par25">The term &#8220;viral shedding&#8221; means the release of oncolytic or virus-based products from a patient through feces, urine, saliva, other secreted fluids, and through the skin (via sores, wounds, etc.) and describes how a viral product is excreted from a patient&#8217;s body [<xref ref-type="bibr" rid="CR53">53</xref>]. It is a separate and distinct process from biodistribution, which describes how the virus is spread within a patient&#8217;s body from the site of administration [<xref ref-type="bibr" rid="CR53">53</xref>]. The potential for viral shedding has resulted in the development of precautionary administration and handling procedures to limit any risk of secondary transmission of oncolytic viruses [<xref ref-type="bibr" rid="CR54">54</xref>]. For example, in trials involving the use of talimogene laherparepvec, a modified HSV-1 virus, all healthcare personnel must wear proper personal-protective equipment (e.g., gown, gloves, safety glasses) when handling the virus, in keeping with universal biohazard procedures [<xref ref-type="bibr" rid="CR53">53</xref>]. The virus is injected into cutaneous, subcutaneous, or nodal lesions with or without ultrasound guidance, and the volume injected is contingent upon the longest lesion size diameter [<xref ref-type="bibr" rid="CR11">11</xref>]. The maximum volume that could be injected is 4&#160;mL [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Once the virus has been administered to the patient, the injection site is disinfected, and after changing gloves, an occlusive dressing is applied. To further minimize the risk of secondary transmission, the outside of the occlusive dressing is disinfected. Materials used for the injection can be disposed of using universal biohazard precautions. If contamination to working surfaces occurs, the contaminated areas are treated with virucidal agents.</p></sec><sec id="Sec5"><title>Current oncolytic viruses and trials</title><p id="Par26">Oncolytic viruses have been or are being evaluated as treatment for a variety of malignancies. The first clinical trials using an engineered virus began in the 1990s [<xref ref-type="bibr" rid="CR55">55</xref>], and a recent search of ClinicalTrials.gov identified approximately 1800 trials involving viruses and cancer. A select number of these are summarized in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>, and some representative oncolytic viruses are further elaborated in this section. For example, an engineered H101 variant of adenovirus was approved in China in 2005 for the treatment of nasopharyngeal carcinoma when used in combination with cisplatin [<xref ref-type="bibr" rid="CR56">56</xref>]. Other viruses under investigation that have recently shown promising results in melanoma include CVA21 (also known as Cavatak), a bioselected variant of coxsackie virus A21, and HF10, a replication-competent oncolytic virus derived from HSV-1 [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>]. The most clinically advanced oncolytic immunotherapy is talimogene laherparepvec, a recombinant HSV-1 virus expressing GM-CSF [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR24">24</xref>] which recently received approval by the United States Food and Drug Administration, the European Medicines Agency, and the Australian Therapeutic Goods Administration for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma.</p><p id="Par27">Talimogene laherparepvec is a first-in-class oncolytic virus that has been genetically engineered to selectively replicate within tumor cells when directly injected into lesions and to express GM-CSF to enhance systemic antitumor immune responses. Two viral genes, <italic>ICP34.5</italic> (at two loci) and <italic>ICP47</italic>, were deleted to promote selective replication in tumor cells and to enhance antigen presentation of HSV-infected cells, thus augmenting the immunostimulatory properties of the virus [<xref ref-type="bibr" rid="CR59">59</xref>] (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). The insertion of GM-CSF serves to supplement the antitumor immune response through the recruitment of antigen-presenting cells [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>] (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig3"><label>Fig.&#160;3</label><caption><p>Genetic modifications of talimogene laherparepvec. The viral gene ICP34.5 was deleted and replaced with a human granulocyte-macrophage colony-stimulating factor (hGM-CSF) expression cassette comprising the cytomegalovirus (CMV) promoter, hGM-CSF, and a bovine growth hormone polyadenylation (pA) signal. Expression of the viral gene US11 is driven by the ICP47 promoter</p></caption><graphic xlink:href="262_2017_2025_Fig3_HTML" id="MO3"/></fig>
<fig id="Fig4"><label>Fig.&#160;4</label><caption><p>Talimogene laherparepvec proposed mechanism of action. <italic>CMV</italic> cytomegalovirus, <italic>GM</italic>-<italic>CSF</italic> granulocyte-macrophage colony-stimulating factor, <italic>hGM</italic>-<italic>CSF</italic> human GM-CSF, <italic>pA</italic> poly-adenosine, <italic>TDA</italic> tumor-derived antigen</p></caption><graphic xlink:href="262_2017_2025_Fig4_HTML" id="MO4"/></fig>
</p><p id="Par28">
<italic>ICP34.5</italic>- and <italic>ICP47</italic>-deleted HSV with GM-CSF expression has been shown to increase tumor shrinkage in noninjected tumors and improve the extent of the systemic antitumor response postinjection when compared with the <italic>ICP34.5</italic>- and <italic>ICP47</italic>-deleted HSV without GM-CSF in a syngeneic A20 tumor model [<xref ref-type="bibr" rid="CR59">59</xref>]. An increase in interferon-&#947; levels in splenocytes isolated from mice treated with <italic>ICP34.5</italic>- and <italic>ICP47</italic>-deleted HSV expressing GM-CSF was observed when compared with those treated with <italic>ICP34.5</italic>- and <italic>ICP47</italic>-deleted HSV without GM-CSF [<xref ref-type="bibr" rid="CR59">59</xref>]. Furthermore mice in which tumors were previously cleared by injection with the GM-CSF&#8211;expressing mutant HSV were protected against tumor development for 6&#160;months when rechallenged with tumor cells. This implied a systemic antitumor immunity [<xref ref-type="bibr" rid="CR59">59</xref>]. Clinical data also supported this implication. Results from a phase 2 analysis found an increase in melanoma-associated antigen recognized by T-cells (MART-1)&#8211;specific T-cells in tumors from patients treated with talimogene laherparepvec compared with tumors from untreated patients [<xref ref-type="bibr" rid="CR62">62</xref>]. Moreover, a significant decrease in regulatory T-cells, suppressor T-cells, and myeloid-derived suppressor cells was observed in injected lesions compared with noninjected lesions in the same and different patients [<xref ref-type="bibr" rid="CR62">62</xref>].</p><p id="Par29">As noted in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>, oncolytic viruses are currently being evaluated both as monotherapies and as part of combination therapies in a large number of ongoing trials. Some representative studies are further elaborated in this section [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. OPTiM, the first randomized phase 3 clinical trial of an oncolytic virus, evaluated durable responses in patients with unresectable stage IIIB/IIIC/IV melanoma (<italic>N</italic>&#160;=&#160;436). The primary endpoint was durable response rate (DRR), defined as the rate of complete response (CR) plus PR lasting &#8805;6&#160;months continuously and beginning within the first 12&#160;months.</p><p id="Par30">The study met its primary endpoint. Talimogene laherparepvec resulted in a DRR of 16.3% compared with 2.1% for patients treated with subcutaneous GM-CSF (<italic>P</italic>&#160;&lt;&#160;0.001) [<xref ref-type="bibr" rid="CR11">11</xref>]. The overall response rate (ORR) was 26.4% for patients treated with talimogene laherparepvec compared with 5.7% for patients treated with GM-CSF [<xref ref-type="bibr" rid="CR11">11</xref>]. Notably, responses (defined as &#8805;50% decrease in area at a single time point) were observed at uninjected visceral and nonvisceral lesions, indicating that regional and distant systemic antitumor immune responses also occurred. Median overall survival (OS) was 23.3&#160;months with talimogene laherparepvec and 18.9&#160;months with GM-CSF (hazard ratio&#160;=&#160;0.79; 95% CI&#160;=&#160;0.62&#8211;1.00; <italic>P</italic>&#160;=&#160;0.051; Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>) [<xref ref-type="bibr" rid="CR11">11</xref>].<fig id="Fig5"><label>Fig.&#160;5</label><caption><p>Overall survival after talimogene laherparepvec administration. <italic>GM</italic>-<italic>CSF</italic> granulocyte-macrophage colony-stimulating factor, <italic>OS</italic> overall survival, <italic>T</italic>-<italic>VEC</italic> talimogene laherparepvec.</p><p>Reprinted with permission from Andtbacka et al. [<xref ref-type="bibr" rid="CR11">11</xref>]</p></caption><graphic xlink:href="262_2017_2025_Fig5_HTML" id="MO5"/></fig>
</p><p id="Par31">Exploratory subgroup analyses were performed to investigate the treatment effect across key covariates for DRR, ORR, and OS [<xref ref-type="bibr" rid="CR11">11</xref>]. Differences in DRR between the talimogene laherparepvec and GM&#8208;CSF arms were more pronounced in patients with stage IIIB/C (33 versus 0%) and IVM1a (16 versus 2%) disease than in patients with stage IVM1b (3 versus 4%) and IVM1c (8 versus 3%) disease [<xref ref-type="bibr" rid="CR11">11</xref>]. Differences in DRR were also more pronounced in patients with treatment&#8208;naive metastatic melanoma (24 versus 0%) than in those receiving treatment as second line or later therapy (10 versus 4%) [<xref ref-type="bibr" rid="CR11">11</xref>]. A similar pattern was seen for ORR in these subgroups [<xref ref-type="bibr" rid="CR11">11</xref>]. Treatment effects of talimogene laherparepvec on OS were more pronounced among patients with stage IIIB/C and IVM1a disease (hazard ratio&#160;=&#160;0.57; 95% CI&#160;=&#160;0.40&#8211;0.80; <italic>n</italic>&#160;=&#160;249) compared with patients with IVM1b or IVM1c disease (hazard ratio&#160;=&#160;1.07; 95% CI&#160;=&#160;0.75&#8211;1.52; <italic>n</italic>&#160;=&#160;186) and among patients with treatment&#8208;naive metastatic melanoma (hazard ratio&#160;=&#160;0.50; 95% CI&#160;=&#160;0.35&#8211;0.73; <italic>n</italic>&#160;=&#160;203) compared with those receiving talimogene laherparepvec second&#8208;line or greater therapy (hazard ratio&#160;=&#160;1.13; 95% CI&#160;=&#160;0.82&#8211;1.57; <italic>n</italic>&#160;=&#160;233) [<xref ref-type="bibr" rid="CR11">11</xref>]. Although the reasons for the significant differences in DRR, ORR, and OS observed in patients with stage IIIB/IIIC/IVM1a disease compared with patients with stage IVM1b/IVM1c disease are unknown, these differences might be explained by the talimogene laherparepvec mechanism of action. Disease control in patients with stage IIIB/IIIC or IVM1a disease requires locoregional immune effects, whereas disease control for patients with stage IVM1b or IVM1c disease (i.e., patients with lung or other visceral organ metastases) requires a systemic immune response. It is possible that injection into nonvisceral lesions may activate a systemic immune response that is preferentially directed toward similar metastatic sites rather than to visceral lesions presenting a different antigen pattern [<xref ref-type="bibr" rid="CR11">11</xref>]. Alternatively, patients with more advanced visceral disease may not have survived long enough to develop systemic antitumor immunity. Differences in overall survival by line of therapy might be explained by the development of immunological defense mechanisms in previously treated tumors, immunosuppressive effects of chemotherapy, or higher baseline tumor burden. Adverse events (AEs; any grade) that occurred most frequently with talimogene laherparepvec treatment included fatigue (50.3%), chills (48.6%), and pyrexia (42.8%) [<xref ref-type="bibr" rid="CR11">11</xref>]. The most common high-grade AE in the talimogene laherparepvec arm was cellulitis (2.1%) [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par32">At the time of the final analysis, conducted 3&#160;years after the last patient was randomized, median (range) follow-up was 49 (37&#8211;63) months [<xref ref-type="bibr" rid="CR63">63</xref>]. Median (95% CI) OS was 23.3 (19.5&#8211;29.6) months for patients in the talimogene laherparepvec arm and 18.9 (16.0&#8211;23.8) months for patients in the GM-CSF arm (hazard ratio&#160;=&#160;0.80; 95% CI&#160;=&#160;0.62&#8211;1.00; <italic>P</italic>&#160;=&#160;0.0494, descriptive) [<xref ref-type="bibr" rid="CR63">63</xref>]. The 5-year survival rate for patients in the talimogene laherparepvec arm was 33.4% (95% CI&#160;=&#160;27.7&#8211;39.2) [<xref ref-type="bibr" rid="CR63">63</xref>].</p><p id="Par33">In a follow-up analysis of the OPTiM trial, 23 of the 48 (48%) patients treated with talimogene laherparepvec who had a durable response experienced progression before response, including 14 patients who developed new lesions only [<xref ref-type="bibr" rid="CR47">47</xref>]. Pseudoprogression was not found to have a negative impact on survival in this analysis [<xref ref-type="bibr" rid="CR47">47</xref>].</p><p id="Par34">Further evidence for the activity of oncolytic agents as single-agent therapies is being provided by recent or ongoing investigations. Other oncolytic agents currently being assessed in phase 3 studies include CG0070, a replication-sensitive adenovirus expressing GM-CSF being evaluated in patients with bladder cancer, and pexastimogene devacirepvec (previously, JX-594 or PexaVec), a modified vaccinia virus currently being evaluated in patients with hepatocellular carcinoma (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). In a phase 1 study, the response rate among patients with non&#8211;muscle-invasive bladder cancer treated with intravesical infusions of CG0070 every 28&#160;days for three cycles or weekly for six cycles was 48.6% (17/35), and patients treated with the lowest dose [1&#160;&#215;&#160;10<sup>12</sup> viral particles (vp)] across all treatment schedules had the highest rate of CR (61.5%) compared with other dose levels (range 0&#8211;44%) [<xref ref-type="bibr" rid="CR64">64</xref>]. A median duration of CR of 10.4&#160;months was achieved, with some responses continuing after 17.0&#160;months [<xref ref-type="bibr" rid="CR64">64</xref>]. Most AEs were grade 1&#8211;2, and none were clinically significant. The most common AE observed was dysuria (71.4%) [<xref ref-type="bibr" rid="CR64">64</xref>]. An open-label, single-arm phase 3 multicenter study of the safety and efficacy of CG0070 in patients with non&#8211;muscle-invasive bladder carcinoma who have failed Bacillus Calmette&#8211;Gu&#233;rin therapy and refused cystectomy is currently ongoing (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par35">In a small dose-finding study (<italic>n</italic>&#160;=&#160;49), treatment of patients with advanced hepatocellular carcinoma with three infusions of intravenous pexastimogene devacirepvec resulted in four objective responses (one CR, three PRs), and ten patients had stable disease [<xref ref-type="bibr" rid="CR65">65</xref>]. The median OS for all patients was 9.0&#160;months. Median OS was significantly longer for patients in the high-dose group (10<sup>9</sup> PFU; 14.1&#160;months) compared with the low-dose group (10<sup>8</sup> PFU; 6.7&#160;months; hazard ratio&#160;=&#160;0.39; <italic>P</italic>&#160;=&#160;0.02) [<xref ref-type="bibr" rid="CR65">65</xref>]. Grade 1&#8211;2 flu-like symptoms occurred in all patients over the first 12&#8211;24&#160;h of treatment; patients in the high-dose group showed a greater temperature increase compared with those in the low-dose group (<italic>P</italic>&#160;=&#160;0.002); one grade 4 event of lymphopenia was reported in a patient in the high-dose group [<xref ref-type="bibr" rid="CR65">65</xref>]. A phase 3 randomized, open-label study comparing pexastimogen devacirepvec followed by sorafenib versus sorafenib in patients with advanced hepatocellular carcinoma without prior systemic therapy is currently ongoing (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par36">Initial studies using CVA21 (also known as Cavatak), a bioselected variant of coxsackie virus A21, have been conducted in melanoma, prostate cancer, and breast cancer cell lines and in xenografts in vivo; these cell types all express high levels of receptors (e.g., ICAM-1) that the virus requires for productive infection [<xref ref-type="bibr" rid="CR66">66</xref>&#8211;<xref ref-type="bibr" rid="CR68">68</xref>]. In all studies, CVA21 infection produced targeted virus-induced oncolysis in both cell culture assays and tumor xenografts [<xref ref-type="bibr" rid="CR66">66</xref>&#8211;<xref ref-type="bibr" rid="CR68">68</xref>]. In a phase 1 study of patients with stage IV melanoma, five of the nine patients injected with CVA21 had transient/stable reductions in injected tumor volume or tumor stabilization, and two patients had stable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 [<xref ref-type="bibr" rid="CR69">69</xref>]. In a phase 2 study of CVA21 in patients with stage IIIC/IV melanoma (<italic>N</italic>&#160;=&#160;57), the immune-related 1-year progression-free survival rate was 28% and the 1-year survival rate was 75% [<xref ref-type="bibr" rid="CR70">70</xref>]. Initial studies for tolerance of CVA21 are underway in patients with non&#8211;muscle-invasive bladder cancer; preliminary results indicate clinical activity and notable signs of viral-induced tumor inflammation [<xref ref-type="bibr" rid="CR71">71</xref>]. Reolysin<sup>&#174;</sup>, a naturally occurring, unmodified strain of reovirus known for exploiting activated <italic>RAS</italic> signaling, has recently undergone phase 1 and 2 studies in patients with solid tumors [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR72">72</xref>], and was granted Orphan Drug Designation by the United States Food and Drug Administration in 2015 for the treatment of ovarian cancer [<xref ref-type="bibr" rid="CR73">73</xref>]. In the most recent study of patients with solid tumors (<italic>N</italic>&#160;=&#160;19), treatment was well tolerated in injected patients, and all symptomatic toxicities were mild (grade &#8804;2) [<xref ref-type="bibr" rid="CR49">49</xref>]. The most frequently reported AEs were nausea (79%), vomiting (58%), headache (63%), local erythema of injection site (42%), fever and/or chills (37%), dizziness (37%), flu-like symptoms (32%), and diarrhea (32%) [<xref ref-type="bibr" rid="CR49">49</xref>]. All patients were negative for viral shedding. Best target tumor responses of CR, PR, and stable disease were observed in one patient (5.3%), two patients (10.5%), and four patients (21.1%), respectively [<xref ref-type="bibr" rid="CR49">49</xref>]. A randomized study of Reolysin<sup>&#174;</sup> plus chemotherapy in patients with squamous cell carcinoma of the head and neck showed statistically significant improvement in progression-free survival (hazard ratio&#160;=&#160;0.536; <italic>P</italic>&#160;=&#160;0.007) and OS (hazard ratio&#160;=&#160;0.510; <italic>P</italic>&#160;=&#160;0.015) compared with chemotherapy alone (ClinicalTrials.gov identifier, NCT01166542); however, it must be noted that this study was not registrational quality [<xref ref-type="bibr" rid="CR74">74</xref>].</p><p id="Par37">In addition to use as single-agent therapies, oncolytic viruses may have utility when combined with other cancer therapies. In particular, combination of agents (such as oncolytic immunotherapies) that increase tumor-specific immune responses and those that block inhibitory T-cell checkpoints may result in improved antitumor activity compared with treatment with either agent alone. To this end, studies evaluating talimogene laherparepvec in combination with checkpoint inhibitors are currently ongoing. A phase 1b/2 study is assessing combination treatment with talimogene laherparepvec and ipilimumab in patients with melanoma. Results from the phase 1b study (<italic>N</italic>&#160;=&#160;19) revealed a confirmed ORR by irRC of 50% [<xref ref-type="bibr" rid="CR50">50</xref>]. In addition, a disease control rate of 72% (CR, 22%; PR, 28%; stable disease, 22%) was observed with combination treatment [<xref ref-type="bibr" rid="CR50">50</xref>]. A durable response (CR or PR lasting &#8805;6&#160;months) occurred in eight patients (44%). Combination therapy with talimogene laherparepvec plus ipilimumab had a median time to response of 5.3&#160;months; initial data indicate disease control within all disease stages [<xref ref-type="bibr" rid="CR50">50</xref>]. The most common AEs (any grade) were chills, fatigue, and pyrexia (all 58%) [<xref ref-type="bibr" rid="CR50">50</xref>]. In December 2014, a phase 1b/3, multicenter, open-label trial of talimogene laherparepvec in combination with pembrolizumab for previously untreated, unresected, stage IIIB to IVM1c melanoma was initiated (estimated enrollment, <italic>N</italic>&#160;=&#160;660) with the goal of enhancing the antitumor response to either treatment alone [<xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR76">76</xref>]. The primary and secondary endpoints of the phase 1b trial include the incidence of dose-limiting toxicities and objective response rate, respectively. Preliminary data from 21 phase 1b patients were presented at the Society for Melanoma Research 2015 Congress [<xref ref-type="bibr" rid="CR77">77</xref>], and updated results were presented at the 2016 ASCO Annual Meeting [<xref ref-type="bibr" rid="CR78">78</xref>]. The data suggested that the combination could be administered at full doses with no unanticipated safety concerns. The most common AEs were fatigue (62%), pyrexia (52%), and chills (48%). Efficacy results indicated that among 21 patients who had received their first dose of pembrolizumab at least 12&#160;weeks earlier and had evaluable response assessments, the unconfirmed response rate per investigator was 57%; 24% of patients had an unconfirmed CR. Of these 48% had a confirmed response, and 14% had a confirmed CR [<xref ref-type="bibr" rid="CR78">78</xref>]. Additional combination studies include the phase 1 STORM (KEYNOTE 200) study, which is evaluating the safety and efficacy of CVA21 in combination with pembrolizumab in patients with non&#8211;small-cell lung cancer and bladder cancer [<xref ref-type="bibr" rid="CR79">79</xref>] and PHOCUS, the randomized phase 3 study of pexastimogene devacirepvec, followed by sorafenib versus sorafenib alone in patients with hepatocellular carcinoma [<xref ref-type="bibr" rid="CR80">80</xref>]. Both studies are currently recruiting participants, with results expected in 2019 and 2017, respectively.</p><p id="Par38">Oncolytic therapy has also been studied in combination with chemotherapy and radiation treatments [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR81">81</xref>&#8211;<xref ref-type="bibr" rid="CR87">87</xref>]. Combination treatment with ONYX-015, cisplatin, and 5-fluorouracil resulted in tumor shrinkage in 25 of 30 cases of head and neck cancer. The ORR for the intent-to-treat population (<italic>N</italic>&#160;=&#160;37) was 53%; 8 (27%) had CR and 11 (36%) had a PR [<xref ref-type="bibr" rid="CR83">83</xref>]. Treatment was well tolerated, and a lack of cross-resistance was seen between chemotherapeutic and virotherapeutic agents [<xref ref-type="bibr" rid="CR83">83</xref>]. Another trial evaluated an adenovirus containing two suicide genes, <italic>CD</italic> and <italic>HSV</italic>-<italic>1 TK</italic>, which convert the prodrug 5-fluorocytosine to 5-fluorouracil and thymidine analogs to their monophosphate analogs, respectively, effectively sensitizing infected cells to ionizing radiation. In a trial of patients with prostate cancer (<italic>N</italic>&#160;=&#160;15) who were treated with the adenovirus, the two prodrugs, and radiation therapy, all patients saw significant declines in prostate antigen levels after combination treatment [<xref ref-type="bibr" rid="CR81">81</xref>]. Lastly, a phase 1 study of ONCOS-102, an adenovirus expressing GM-CSF in combination with cyclophosphamide, was recently completed in patients (<italic>n</italic>&#160;=&#160;10) with solid tumors [<xref ref-type="bibr" rid="CR88">88</xref>]. No dose-limiting toxicities occurred and four patients had disease control at 3&#160;months; median OS was 9.3&#160;months [<xref ref-type="bibr" rid="CR88">88</xref>].</p></sec><sec id="Sec6"><title>The future of oncolytic immunotherapy</title><p id="Par39">Although the theoretical promise of oncolytic immunotherapy has been demonstrated, it is likely that additional gains will require combinatorial treatment with other therapeutic modalities. For example, combination treatment with both immunotherapeutic agents and chemotherapeutic regimens has been evaluated with a number of viral backbones (e.g., ONYX-015, H101, talimogene laherparepvec) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. As mentioned previously, talimogene laherparepvec is currently being evaluated in combination with ipilimumab or pembrolizumab in patients with melanoma, and it is likely that other combinations with checkpoint inhibitors will be investigated in the future.</p><p id="Par40">Furthermore, through genetic modification, there are additional opportunities to engineer oncolytic viruses that specifically deliver different payloads to tumor targets. For example, one study evaluated the antitumor efficacy of a transductionally and transcriptionally targeted oncolytic adenovirus that was armed with a fully human monoclonal antibody targeted toward CTLA4-Ipilimumab (Ad5/3-&#916;aCTLA4) [<xref ref-type="bibr" rid="CR89">89</xref>]. Treatment with the virus was able to activate T-cells from cancer patients, as measured by increases in interleukin-2 and interferon-&#947; levels [<xref ref-type="bibr" rid="CR89">89</xref>]. In addition, a direct apoptotic effect was observed with viral treatment, both in vitro and in vivo, and the apoptotic effect directly correlated with anti-CTLA4 antibody expression with phase 1b response rates over 50% [<xref ref-type="bibr" rid="CR89">89</xref>]. Another example is a genetically engineered rhabdovirus Maraba (MG1) expressing a melanoma-associated tumor antigen, which has been evaluated in preclinical study in mice [<xref ref-type="bibr" rid="CR90">90</xref>]. Alone, the MG1 vaccine does not appear to be sufficient to invoke adaptive immunity against the antigen, but when tested with a heterologous prime-boosting vector (recombinant adenovirus expressing human dopachrome tautomerase), MG1 quickly generated strong, antigen-specific T-cell responses and prolonged survival [<xref ref-type="bibr" rid="CR90">90</xref>].</p></sec><sec id="Sec7"><title>Conclusion</title><p id="Par41">Oncolytic immunotherapy is a multifaceted and promising treatment option in the field of cancer immunotherapy. The quantity and variety of virus types, genetic modifications introduced, and therapy combinations being evaluated in preclinical and clinical studies are numerous and continuing to grow. It will be interesting to see the progress and potential of these exciting therapeutic strategies in future clinical trials.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AE</term><def><p id="Par2">Adverse event</p></def></def-item><def-item><term>AFP</term><def><p id="Par3">&#945;-Fetoprotein</p></def></def-item><def-item><term>CR</term><def><p id="Par4">Complete response</p></def></def-item><def-item><term>DRR</term><def><p id="Par5">Durable response rate</p></def></def-item><def-item><term>GM-CSF</term><def><p id="Par6">Granulocyte-macrophage colony-stimulating factor</p></def></def-item><def-item><term>HSV-1</term><def><p id="Par7">Herpes simplex virus type 1</p></def></def-item><def-item><term>MART-1</term><def><p id="Par8">Melanoma associated antigen recognized by T-cells</p></def></def-item><def-item><term>ORR</term><def><p id="Par9">Overall response rate</p></def></def-item><def-item><term>OS</term><def><p id="Par10">Overall survival</p></def></def-item><def-item><term>PR</term><def><p id="Par11">Partial response</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>The authors thank Meghan Johnson, PhD (Complete Healthcare Communications, LLC), for medical writing assistance in the preparation of this manuscript. Their work was funded by Amgen Inc.</p></ack><notes notes-type="COI-statement"><title>Compliance with ethical standards</title><sec id="FPar1"><title>Conflict of interest</title><p id="Par42">Omid Hamid has been an investigator, consultant, and speaker for Amgen Inc. Brianna Hoffner has been a consultant to Merck, Novartis, Genentech, and Amgen Inc., but has not had consulting relationships with any company since October 2015. Eduard Gasal was an employee of and stockholder in Amgen Inc. at the time the manuscript was written. Richard D. Carvajal has been a consultant to Novartis, AstraZeneca, Merck, Bristol-Myers Squibb, Roche/Genetech, Janssen, Thomas Reuters, Aura Biosciences, Iconic Therapeutics, Rgenix, and Castle Biosciences; has served on scientific advisory boards for Aura Biosciences; and has served on clinical advisory boards for Rgenix. Jenny Hong has no conflicts to disclose. All authors participated in literature research and drafting the manuscript.</p></sec><sec id="FPar2"><title>Funding</title><p id="Par43">Support for medical writing assistance and for the development of this article was provided by Amgen Inc. All content was per the authors&#8217; direction.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>TC</given-names></name><name><surname>Galanis</surname><given-names>E</given-names></name><name><surname>Kirn</surname><given-names>D</given-names></name></person-group><article-title>Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress</article-title><source>Nat Clin Pract Oncol</source><year>2007</year><volume>4</volume><fpage>101</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1038/ncponc0736</pub-id><?supplied-pmid 17259931?><pub-id pub-id-type="pmid">17259931</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dock</surname><given-names>G</given-names></name></person-group><article-title>The influence of complicating diseases upon leukaemia</article-title><source>Am J Med Sci</source><year>1904</year><volume>127</volume><fpage>563</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1097/00000441-190412740-00001</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Pace</surname><given-names>N</given-names></name></person-group><article-title>Sulla scomparsa di un enorme cancro vegetante del collo dell&#8217;utero senza cura chirurgica</article-title><source>Ginecologia</source><year>1912</year><volume>9</volume><fpage>82</fpage><lpage>89</lpage></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asada</surname><given-names>T</given-names></name></person-group><article-title>Treatment of human cancer with mumps virus</article-title><source>Cancer</source><year>1974</year><volume>34</volume><fpage>1907</fpage><lpage>1928</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(197412)34:6&lt;1907::AID-CNCR2820340609&gt;3.0.CO;2-4</pub-id><?supplied-pmid 4611607?><pub-id pub-id-type="pmid">4611607</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasquinucci</surname><given-names>G</given-names></name></person-group><article-title>Possible effect of measles on leukaemia</article-title><source>Lancet</source><year>1971</year><volume>1</volume><fpage>136</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(71)90869-5</pub-id><?supplied-pmid 4099624?><pub-id pub-id-type="pmid">4099624</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bluming</surname><given-names>AZ</given-names></name><name><surname>Ziegler</surname><given-names>JL</given-names></name></person-group><article-title>Regression of Burkitt&#8217;s lymphoma in association with measles infection</article-title><source>Lancet</source><year>1971</year><volume>2</volume><fpage>105</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(71)92086-1</pub-id><?supplied-pmid 4103972?><pub-id pub-id-type="pmid">4103972</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huebner</surname><given-names>RJ</given-names></name><name><surname>Rowe</surname><given-names>WP</given-names></name><name><surname>Schatten</surname><given-names>WE</given-names></name><name><surname>Smith</surname><given-names>RR</given-names></name><name><surname>Thomas</surname><given-names>LB</given-names></name></person-group><article-title>Studies on the use of viruses in the treatment of carcinoma of the cervix</article-title><source>Cancer</source><year>1956</year><volume>9</volume><fpage>1211</fpage><lpage>1218</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(195611/12)9:6&lt;1211::AID-CNCR2820090624&gt;3.0.CO;2-7</pub-id><?supplied-pmid 13383455?><pub-id pub-id-type="pmid">13383455</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toolan</surname><given-names>HW</given-names></name><name><surname>Saunders</surname><given-names>EL</given-names></name><name><surname>Southam</surname><given-names>CM</given-names></name><name><surname>Moore</surname><given-names>AE</given-names></name><name><surname>Levin</surname><given-names>AG</given-names></name></person-group><article-title>H-1 virus viremia in the human</article-title><source>Proc Soc Exp Biol Med</source><year>1965</year><volume>119</volume><fpage>711</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.3181/00379727-119-30278</pub-id><?supplied-pmid 14328982?><pub-id pub-id-type="pmid">14328982</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheelock</surname><given-names>EF</given-names></name><name><surname>Dingle</surname><given-names>JH</given-names></name></person-group><article-title>Observations on the repeated administration of viruses to a patient with acute leukemia. A preliminary report</article-title><source>N Engl J Med</source><year>1964</year><volume>271</volume><fpage>645</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1056/NEJM196409242711302</pub-id><?supplied-pmid 14170843?><pub-id pub-id-type="pmid">14170843</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>ES</given-names></name><name><surname>Xing</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>RH</given-names></name><name><surname>Shafren</surname><given-names>DR</given-names></name></person-group><article-title>Enhanced cellular receptor usage by a bioselected variant of coxsackievirus A21</article-title><source>J Virol</source><year>2004</year><volume>78</volume><fpage>12603</fpage><lpage>12612</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.22.12603-12612.2004</pub-id><?supplied-pmid 15507647?><pub-id pub-id-type="pmid">15507647</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andtbacka</surname><given-names>RH</given-names></name><name><surname>Kaufman</surname><given-names>HL</given-names></name><name><surname>Collichio</surname><given-names>F</given-names></name><name><surname>Amatruda</surname><given-names>T</given-names></name><name><surname>Senzer</surname><given-names>N</given-names></name><name><surname>Chesney</surname><given-names>J</given-names></name><name><surname>Delman</surname><given-names>KA</given-names></name><name><surname>Spitler</surname><given-names>LE</given-names></name><name><surname>Puzanov</surname><given-names>I</given-names></name><name><surname>Agarwala</surname><given-names>SS</given-names></name><name><surname>Milhem</surname><given-names>M</given-names></name><name><surname>Cranmer</surname><given-names>L</given-names></name><name><surname>Curti</surname><given-names>B</given-names></name><name><surname>Lewis</surname><given-names>K</given-names></name><name><surname>Ross</surname><given-names>M</given-names></name><name><surname>Guthrie</surname><given-names>T</given-names></name><name><surname>Linette</surname><given-names>GP</given-names></name><name><surname>Daniels</surname><given-names>GA</given-names></name><name><surname>Harrington</surname><given-names>K</given-names></name><name><surname>Middleton</surname><given-names>MR</given-names></name><name><surname>Miller</surname><given-names>WH</given-names><suffix>Jr</suffix></name><name><surname>Zager</surname><given-names>JS</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Doleman</surname><given-names>S</given-names></name><name><surname>VanderWalde</surname><given-names>A</given-names></name><name><surname>Gansert</surname><given-names>J</given-names></name><name><surname>Coffin</surname><given-names>RS</given-names></name></person-group><article-title>Talimogene laherparepvec improves durable response rate in patients with advanced melanoma</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><fpage>2780</fpage><lpage>2788</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.58.3377</pub-id><?supplied-pmid 26014293?><pub-id pub-id-type="pmid">26014293</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elsedawy</surname><given-names>NB</given-names></name><name><surname>Russell</surname><given-names>SJ</given-names></name></person-group><article-title>Oncolytic vaccines</article-title><source>Expert Rev Vaccines</source><year>2013</year><volume>12</volume><fpage>1155</fpage><lpage>1172</lpage><pub-id pub-id-type="doi">10.1586/14760584.2013.836912</pub-id><?supplied-pmid 24124877?><pub-id pub-id-type="pmid">24124877</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullen</surname><given-names>JT</given-names></name><name><surname>Tanabe</surname><given-names>KK</given-names></name></person-group><article-title>Viral oncolysis</article-title><source>Oncologist</source><year>2002</year><volume>7</volume><fpage>106</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.7-2-106</pub-id><?supplied-pmid 11961194?><pub-id pub-id-type="pmid">11961194</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanziale</surname><given-names>SF</given-names></name><name><surname>Petrowsky</surname><given-names>H</given-names></name><name><surname>Adusumilli</surname><given-names>PS</given-names></name><name><surname>Ben-Porat</surname><given-names>L</given-names></name><name><surname>Gonen</surname><given-names>M</given-names></name><name><surname>Fong</surname><given-names>Y</given-names></name></person-group><article-title>Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>3225</fpage><lpage>3232</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-1083-3</pub-id><?supplied-pmid 15131064?><pub-id pub-id-type="pmid">15131064</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pol</surname><given-names>JG</given-names></name><name><surname>Ress&#233;guier</surname><given-names>J</given-names></name><name><surname>Lichty</surname><given-names>BD</given-names></name></person-group><article-title>Oncolytic viruses: a step into cancer immunotherapy</article-title><source>Virus Adapt Treat</source><year>2012</year><volume>4</volume><fpage>1</fpage><lpage>21</lpage></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Secchiero</surname><given-names>P</given-names></name><name><surname>Flamand</surname><given-names>L</given-names></name><name><surname>Gibellini</surname><given-names>D</given-names></name><name><surname>Falcieri</surname><given-names>E</given-names></name><name><surname>Robuffo</surname><given-names>I</given-names></name><name><surname>Capitani</surname><given-names>S</given-names></name><name><surname>Gallo</surname><given-names>RC</given-names></name><name><surname>Zauli</surname><given-names>G</given-names></name></person-group><article-title>Human herpesvirus 7 induces CD4(+) T-cell death by two distinct mechanisms: necrotic lysis in productively infected cells and apoptosis in uninfected or nonproductively infected cells</article-title><source>Blood</source><year>1997</year><volume>90</volume><fpage>4502</fpage><lpage>4512</lpage><?supplied-pmid 9373261?><pub-id pub-id-type="pmid">9373261</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ullrich</surname><given-names>CK</given-names></name><name><surname>Groopman</surname><given-names>JE</given-names></name><name><surname>Ganju</surname><given-names>RK</given-names></name></person-group><article-title>HIV-1 gp120- and gp160-induced apoptosis in cultured endothelial cells is mediated by caspases</article-title><source>Blood</source><year>2000</year><volume>96</volume><fpage>1438</fpage><lpage>1442</lpage><?supplied-pmid 10942389?><pub-id pub-id-type="pmid">10942389</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>PK</given-names></name><name><surname>Doley</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>GR</given-names></name><name><surname>Sahoo</surname><given-names>AP</given-names></name><name><surname>Tiwari</surname><given-names>AK</given-names></name></person-group><article-title>Oncolytic viruses and their specific targeting to tumour cells</article-title><source>Indian J Med Res</source><year>2012</year><volume>136</volume><fpage>571</fpage><lpage>584</lpage><?supplied-pmid 23168697?><pub-id pub-id-type="pmid">23168697</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>HH</given-names></name><name><surname>Lemoine</surname><given-names>NR</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Oncolytic viruses for cancer therapy: overcoming the obstacles</article-title><source>Viruses</source><year>2010</year><volume>2</volume><fpage>78</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.3390/v2010078</pub-id><?supplied-pmid 20543907?><pub-id pub-id-type="pmid">20543907</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danen-van Oorschot</surname><given-names>AA</given-names></name><name><surname>van Der Eb</surname><given-names>AJ</given-names></name><name><surname>Noteborn</surname><given-names>MH</given-names></name></person-group><article-title>The chicken anemia virus-derived protein apoptin requires activation of caspases for induction of apoptosis in human tumor cells</article-title><source>J Virol</source><year>2000</year><volume>74</volume><fpage>7072</fpage><lpage>7078</lpage><pub-id pub-id-type="doi">10.1128/JVI.74.15.7072-7078.2000</pub-id><?supplied-pmid 10888647?><pub-id pub-id-type="pmid">10888647</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breitbach</surname><given-names>CJ</given-names></name><name><surname>Arulanandam</surname><given-names>R</given-names></name><name><surname>De Silva</surname><given-names>N</given-names></name><name><surname>Thorne</surname><given-names>SH</given-names></name><name><surname>Patt</surname><given-names>R</given-names></name><name><surname>Daneshmand</surname><given-names>M</given-names></name><name><surname>Moon</surname><given-names>A</given-names></name><name><surname>Ilkow</surname><given-names>C</given-names></name><name><surname>Burke</surname><given-names>J</given-names></name><name><surname>Hwang</surname><given-names>TH</given-names></name><name><surname>Heo</surname><given-names>J</given-names></name><name><surname>Cho</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Angarita</surname><given-names>FA</given-names></name><name><surname>Addison</surname><given-names>C</given-names></name><name><surname>McCart</surname><given-names>JA</given-names></name><name><surname>Bell</surname><given-names>JC</given-names></name><name><surname>Kirn</surname><given-names>DH</given-names></name></person-group><article-title>Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans</article-title><source>Cancer Res</source><year>2013</year><volume>73</volume><fpage>1265</fpage><lpage>1275</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-2687</pub-id><?supplied-pmid 23393196?><pub-id pub-id-type="pmid">23393196</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breitbach</surname><given-names>CJ</given-names></name><name><surname>Paterson</surname><given-names>JM</given-names></name><name><surname>Lemay</surname><given-names>CG</given-names></name><name><surname>Falls</surname><given-names>TJ</given-names></name><name><surname>McGuire</surname><given-names>A</given-names></name><name><surname>Parato</surname><given-names>KA</given-names></name><name><surname>Stojdl</surname><given-names>DF</given-names></name><name><surname>Daneshmand</surname><given-names>M</given-names></name><name><surname>Speth</surname><given-names>K</given-names></name><name><surname>Kirn</surname><given-names>D</given-names></name><name><surname>McCart</surname><given-names>JA</given-names></name><name><surname>Atkins</surname><given-names>H</given-names></name><name><surname>Bell</surname><given-names>JC</given-names></name></person-group><article-title>Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow</article-title><source>Mol Ther</source><year>2007</year><volume>15</volume><fpage>1686</fpage><lpage>1693</lpage><pub-id pub-id-type="doi">10.1038/sj.mt.6300215</pub-id><?supplied-pmid 17579581?><pub-id pub-id-type="pmid">17579581</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>JCC</given-names></name><name><surname>Coffin</surname><given-names>RS</given-names></name><name><surname>Davis</surname><given-names>CJ</given-names></name></person-group><article-title>A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>6737</fpage><lpage>6747</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-0759</pub-id><?supplied-pmid 17121894?><pub-id pub-id-type="pmid">17121894</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Senzer</surname><given-names>NN</given-names></name><name><surname>Kaufman</surname><given-names>HL</given-names></name><name><surname>Amatruda</surname><given-names>T</given-names></name><name><surname>Nemunaitis</surname><given-names>M</given-names></name><name><surname>Reid</surname><given-names>T</given-names></name><name><surname>Daniels</surname><given-names>G</given-names></name><name><surname>Gonzalez</surname><given-names>R</given-names></name><name><surname>Glaspy</surname><given-names>J</given-names></name><name><surname>Whitman</surname><given-names>E</given-names></name><name><surname>Harrington</surname><given-names>K</given-names></name><name><surname>Goldsweig</surname><given-names>H</given-names></name><name><surname>Marshall</surname><given-names>T</given-names></name><name><surname>Love</surname><given-names>C</given-names></name><name><surname>Coffin</surname><given-names>R</given-names></name><name><surname>Nemunaitis</surname><given-names>JJ</given-names></name></person-group><article-title>Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>5763</fpage><lpage>5771</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.24.3675</pub-id><?supplied-pmid 19884534?><pub-id pub-id-type="pmid">19884534</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>BH</given-names></name><name><surname>Hwang</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>TC</given-names></name><name><surname>Sze</surname><given-names>DY</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Kwon</surname><given-names>HC</given-names></name><name><surname>Oh</surname><given-names>SY</given-names></name><name><surname>Han</surname><given-names>SY</given-names></name><name><surname>Yoon</surname><given-names>JH</given-names></name><name><surname>Hong</surname><given-names>SH</given-names></name><name><surname>Moon</surname><given-names>A</given-names></name><name><surname>Speth</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>C</given-names></name><name><surname>Ahn</surname><given-names>YJ</given-names></name><name><surname>Daneshmand</surname><given-names>M</given-names></name><name><surname>Rhee</surname><given-names>BG</given-names></name><name><surname>Pinedo</surname><given-names>HM</given-names></name><name><surname>Bell</surname><given-names>JC</given-names></name><name><surname>Kirn</surname><given-names>DH</given-names></name></person-group><article-title>Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial</article-title><source>Lancet Oncol</source><year>2008</year><volume>9</volume><fpage>533</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(08)70107-4</pub-id><?supplied-pmid 18495536?><pub-id pub-id-type="pmid">18495536</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Lou</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers</article-title><source>Cancer Biol Ther</source><year>2009</year><volume>8</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.4161/cbt.8.8.7913</pub-id><?supplied-pmid 19242097?><pub-id pub-id-type="pmid">19242097</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edukulla</surname><given-names>R</given-names></name><name><surname>Woller</surname><given-names>N</given-names></name><name><surname>Mundt</surname><given-names>B</given-names></name><name><surname>Knocke</surname><given-names>S</given-names></name><name><surname>Gurlevik</surname><given-names>E</given-names></name><name><surname>Saborowski</surname><given-names>M</given-names></name><name><surname>Malek</surname><given-names>N</given-names></name><name><surname>Manns</surname><given-names>MP</given-names></name><name><surname>Wirth</surname><given-names>T</given-names></name><name><surname>Kuhnel</surname><given-names>F</given-names></name><name><surname>Kubicka</surname><given-names>S</given-names></name></person-group><article-title>Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>1448</fpage><lpage>1458</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-1160</pub-id><?supplied-pmid 19190348?><pub-id pub-id-type="pmid">19190348</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernt</surname><given-names>KM</given-names></name><name><surname>Ni</surname><given-names>S</given-names></name><name><surname>Tieu</surname><given-names>AT</given-names></name><name><surname>Lieber</surname><given-names>A</given-names></name></person-group><article-title>Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>4343</fpage><lpage>4352</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-3527</pub-id><?supplied-pmid 15899826?><pub-id pub-id-type="pmid">15899826</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>O&#8217;Malley</surname><given-names>M</given-names></name><name><surname>Urban</surname><given-names>J</given-names></name><name><surname>Sampath</surname><given-names>P</given-names></name><name><surname>Guo</surname><given-names>ZS</given-names></name><name><surname>Kalinski</surname><given-names>P</given-names></name><name><surname>Thorne</surname><given-names>SH</given-names></name><name><surname>Bartlett</surname><given-names>DL</given-names></name></person-group><article-title>Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer</article-title><source>Mol Ther</source><year>2011</year><volume>19</volume><fpage>650</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1038/mt.2010.312</pub-id><?supplied-pmid 21266959?><pub-id pub-id-type="pmid">21266959</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapteva</surname><given-names>N</given-names></name><name><surname>Aldrich</surname><given-names>M</given-names></name><name><surname>Weksberg</surname><given-names>D</given-names></name><name><surname>Rollins</surname><given-names>L</given-names></name><name><surname>Goltsova</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>SY</given-names></name><name><surname>Huang</surname><given-names>XF</given-names></name></person-group><article-title>Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity</article-title><source>J Immunother</source><year>2009</year><volume>32</volume><fpage>145</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1097/CJI.0b013e318193d31e</pub-id><?supplied-pmid 19238013?><pub-id pub-id-type="pmid">19238013</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauzon</surname><given-names>M</given-names></name><name><surname>Hermiston</surname><given-names>T</given-names></name></person-group><article-title>Armed therapeutic viruses&#8212;a disruptive therapy on the horizon of cancer immunotherapy</article-title><source>Front Immunol</source><year>2014</year><volume>5</volume><fpage>74</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00074</pub-id><?supplied-pmid 24605114?><pub-id pub-id-type="pmid">24605114</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Everts</surname><given-names>B</given-names></name><name><surname>van der Poel</surname><given-names>HG</given-names></name></person-group><article-title>Replication-selective oncolytic viruses in the treatment of cancer</article-title><source>Cancer Gene Ther</source><year>2005</year><volume>12</volume><fpage>141</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1038/sj.cgt.7700771</pub-id><?supplied-pmid 15472714?><pub-id pub-id-type="pmid">15472714</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>IMLYGIC&#8482; (talimogene laherparepvec)</collab></person-group><source>Full prescribing information</source><year>2015</year><publisher-loc>Thousand Oaks</publisher-loc><publisher-name>Amgen Inc.</publisher-name></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>IMLYGICTM&#8482; (talimogene laherparepvec)</collab></person-group><source>Summary of product characteristics</source><year>2016</year><publisher-loc>London</publisher-loc><publisher-name>European Medicines Agency</publisher-name></element-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">IMLYGIC&#8482; (talimogene laherparepvec) Product information (2015). <ext-link ext-link-type="uri" xlink:href="https://www.tga.gov.au/sites/default/files/auspar-talimogene-laherparepvec-160531-pi.pdf">https://www.tga.gov.au/sites/default/files/auspar-talimogene-laherparepvec-160531-pi.pdf</ext-link>. Accessed 27 Feb 2017</mixed-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#8217;Shea</surname><given-names>CC</given-names></name><name><surname>Johnson</surname><given-names>L</given-names></name><name><surname>Bagus</surname><given-names>B</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Nicholas</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>A</given-names></name><name><surname>Boyle</surname><given-names>L</given-names></name><name><surname>Pandey</surname><given-names>K</given-names></name><name><surname>Soria</surname><given-names>C</given-names></name><name><surname>Kunich</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Habets</surname><given-names>G</given-names></name><name><surname>Ginzinger</surname><given-names>D</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name></person-group><article-title>Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity</article-title><source>Cancer Cell</source><year>2004</year><volume>6</volume><fpage>611</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2004.11.012</pub-id><?supplied-pmid 15607965?><pub-id pub-id-type="pmid">15607965</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martuza</surname><given-names>RL</given-names></name></person-group><article-title>Conditionally replicating herpes vectors for cancer therapy</article-title><source>J Clin Invest</source><year>2000</year><volume>105</volume><fpage>841</fpage><lpage>846</lpage><pub-id pub-id-type="doi">10.1172/JCI9744</pub-id><?supplied-pmid 10749560?><pub-id pub-id-type="pmid">10749560</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roizman</surname><given-names>B</given-names></name></person-group><article-title>The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors</article-title><source>Proc Natl Acad Sci USA</source><year>1996</year><volume>93</volume><fpage>11307</fpage><lpage>11312</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.21.11307</pub-id><?supplied-pmid 8876131?><pub-id pub-id-type="pmid">8876131</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallenbeck</surname><given-names>PL</given-names></name><name><surname>Chang</surname><given-names>YN</given-names></name><name><surname>Hay</surname><given-names>C</given-names></name><name><surname>Golightly</surname><given-names>D</given-names></name><name><surname>Stewart</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Phipps</surname><given-names>S</given-names></name><name><surname>Chiang</surname><given-names>YL</given-names></name></person-group><article-title>A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma</article-title><source>Hum Gene Ther</source><year>1999</year><volume>10</volume><fpage>1721</fpage><lpage>1733</lpage><pub-id pub-id-type="doi">10.1089/10430349950017725</pub-id><?supplied-pmid 10428217?><pub-id pub-id-type="pmid">10428217</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melcher</surname><given-names>A</given-names></name><name><surname>Parato</surname><given-names>K</given-names></name><name><surname>Rooney</surname><given-names>CM</given-names></name><name><surname>Bell</surname><given-names>JC</given-names></name></person-group><article-title>Thunder and lightning: immunotherapy and oncolytic viruses collide</article-title><source>Mol Ther</source><year>2011</year><volume>19</volume><fpage>1008</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1038/mt.2011.65</pub-id><?supplied-pmid 21505424?><pub-id pub-id-type="pmid">21505424</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dranoff</surname><given-names>G</given-names></name></person-group><article-title>GM-CSF-secreting melanoma vaccines</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>3188</fpage><lpage>3192</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1206459</pub-id><?supplied-pmid 12789295?><pub-id pub-id-type="pmid">12789295</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prestwich</surname><given-names>RJ</given-names></name><name><surname>Harrington</surname><given-names>KJ</given-names></name><name><surname>Pandha</surname><given-names>HS</given-names></name><name><surname>Vile</surname><given-names>RG</given-names></name><name><surname>Melcher</surname><given-names>AA</given-names></name><name><surname>Errington</surname><given-names>F</given-names></name></person-group><article-title>Oncolytic viruses: a novel form of immunotherapy</article-title><source>Expert Rev Anticancer Ther</source><year>2008</year><volume>8</volume><fpage>1581</fpage><lpage>1588</lpage><pub-id pub-id-type="doi">10.1586/14737140.8.10.1581</pub-id><?supplied-pmid 18925850?><pub-id pub-id-type="pmid">18925850</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Hoos</surname><given-names>A</given-names></name><name><surname>O&#8217;Day</surname><given-names>S</given-names></name><name><surname>Weber</surname><given-names>JS</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name><name><surname>Lebbe</surname><given-names>C</given-names></name><name><surname>Maio</surname><given-names>M</given-names></name><name><surname>Binder</surname><given-names>M</given-names></name><name><surname>Bohnsack</surname><given-names>O</given-names></name><name><surname>Nichol</surname><given-names>G</given-names></name><name><surname>Humphrey</surname><given-names>R</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name></person-group><article-title>Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria</article-title><source>Clin Cancer Res</source><year>2009</year><volume>15</volume><fpage>7412</fpage><lpage>7420</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-1624</pub-id><?supplied-pmid 19934295?><pub-id pub-id-type="pmid">19934295</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerullo</surname><given-names>V</given-names></name><name><surname>Pesonen</surname><given-names>S</given-names></name><name><surname>Diaconu</surname><given-names>I</given-names></name><name><surname>Escutenaire</surname><given-names>S</given-names></name><name><surname>Arstila</surname><given-names>PT</given-names></name><name><surname>Ugolini</surname><given-names>M</given-names></name><name><surname>Nokisalmi</surname><given-names>P</given-names></name><name><surname>Raki</surname><given-names>M</given-names></name><name><surname>Laasonen</surname><given-names>L</given-names></name><name><surname>Sarkioja</surname><given-names>M</given-names></name><name><surname>Rajecki</surname><given-names>M</given-names></name><name><surname>Kangasniemi</surname><given-names>L</given-names></name><name><surname>Guse</surname><given-names>K</given-names></name><name><surname>Helminen</surname><given-names>A</given-names></name><name><surname>Ahtiainen</surname><given-names>L</given-names></name><name><surname>Ristimaki</surname><given-names>A</given-names></name><name><surname>Raisanen-Sokolowski</surname><given-names>A</given-names></name><name><surname>Haavisto</surname><given-names>E</given-names></name><name><surname>Oksanen</surname><given-names>M</given-names></name><name><surname>Karli</surname><given-names>E</given-names></name><name><surname>Karioja-Kallio</surname><given-names>A</given-names></name><name><surname>Holm</surname><given-names>SL</given-names></name><name><surname>Kouri</surname><given-names>M</given-names></name><name><surname>Joensuu</surname><given-names>T</given-names></name><name><surname>Kanerva</surname><given-names>A</given-names></name><name><surname>Hemminki</surname><given-names>A</given-names></name></person-group><article-title>Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><fpage>4297</fpage><lpage>4309</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-3567</pub-id><?supplied-pmid 20484030?><pub-id pub-id-type="pmid">20484030</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Breitbach</surname><given-names>CJ</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Park</surname><given-names>JO</given-names></name><name><surname>Lim</surname><given-names>HY</given-names></name><name><surname>Kang</surname><given-names>WK</given-names></name><name><surname>Moon</surname><given-names>A</given-names></name><name><surname>Mun</surname><given-names>JH</given-names></name><name><surname>Sommermann</surname><given-names>EM</given-names></name><name><surname>Maruri Avidal</surname><given-names>L</given-names></name><name><surname>Patt</surname><given-names>R</given-names></name><name><surname>Pelusio</surname><given-names>A</given-names></name><name><surname>Burke</surname><given-names>J</given-names></name><name><surname>Hwang</surname><given-names>TH</given-names></name><name><surname>Kirn</surname><given-names>D</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name></person-group><article-title>Phase 1b trial of biweekly intravenous pexa-vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus in colorectal cancer</article-title><source>Mol Ther</source><year>2015</year><volume>23</volume><fpage>1532</fpage><lpage>1540</lpage><pub-id pub-id-type="doi">10.1038/mt.2015.109</pub-id><?supplied-pmid 26073886?><pub-id pub-id-type="pmid">26073886</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurra</surname><given-names>V</given-names></name><name><surname>Sullivan</surname><given-names>RJ</given-names></name><name><surname>Gainor</surname><given-names>JF</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name><name><surname>Gandhi</surname><given-names>L</given-names></name><name><surname>Sadow</surname><given-names>CA</given-names></name><name><surname>Harris</surname><given-names>GJ</given-names></name><name><surname>Flaherty</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name></person-group><article-title>Pseudoprogression in cancer immunotherapy: rates, time course and patient outcomes</article-title><source>J Clin Oncol</source><year>2016</year><volume>34</volume><fpage>abstr 6580</fpage></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andtbacka</surname><given-names>RH</given-names></name><name><surname>Ross</surname><given-names>M</given-names></name><name><surname>Puzanov</surname><given-names>I</given-names></name><name><surname>Milhem</surname><given-names>M</given-names></name><name><surname>Collichio</surname><given-names>F</given-names></name><name><surname>Delman</surname><given-names>KA</given-names></name><name><surname>Amatruda</surname><given-names>T</given-names></name><name><surname>Zager</surname><given-names>JS</given-names></name><name><surname>Cranmer</surname><given-names>L</given-names></name><name><surname>Hsueh</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Shilkrut</surname><given-names>M</given-names></name><name><surname>Kaufman</surname><given-names>HL</given-names></name></person-group><article-title>Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial</article-title><source>Ann Surg Oncol</source><year>2016</year><volume>23</volume><fpage>4169</fpage><lpage>4177</lpage><pub-id pub-id-type="doi">10.1245/s10434-016-5286-0</pub-id><?supplied-pmid 27342831?><pub-id pub-id-type="pmid">27342831</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>TC</given-names></name><name><surname>Hwang</surname><given-names>T</given-names></name><name><surname>Park</surname><given-names>BH</given-names></name><name><surname>Bell</surname><given-names>J</given-names></name><name><surname>Kirn</surname><given-names>DH</given-names></name></person-group><article-title>The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma</article-title><source>Mol Ther</source><year>2008</year><volume>16</volume><fpage>1637</fpage><lpage>1642</lpage><pub-id pub-id-type="doi">10.1038/mt.2008.143</pub-id><?supplied-pmid 18628758?><pub-id pub-id-type="pmid">18628758</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>DG</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>DiFrancesco</surname><given-names>LM</given-names></name><name><surname>Fonseca</surname><given-names>K</given-names></name><name><surname>Forsyth</surname><given-names>PA</given-names></name><name><surname>Paterson</surname><given-names>AH</given-names></name><name><surname>Coffey</surname><given-names>MC</given-names></name><name><surname>Thompson</surname><given-names>B</given-names></name></person-group><article-title>REO-001: a phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin&#174;) in patients with advanced solid tumors</article-title><source>Invest New Drugs</source><year>2013</year><volume>31</volume><fpage>696</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1007/s10637-012-9865-z</pub-id><?supplied-pmid 22886613?><pub-id pub-id-type="pmid">22886613</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puzanov</surname><given-names>I</given-names></name><name><surname>Milhem</surname><given-names>MM</given-names></name><name><surname>Andtbacka</surname><given-names>RHI</given-names></name><name><surname>Minor</surname><given-names>DR</given-names></name><name><surname>Hamid</surname><given-names>O</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Chou</surname><given-names>J</given-names></name><name><surname>Kaufman</surname><given-names>H</given-names></name></person-group><article-title>Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><fpage>abstr 9063</fpage></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sze</surname><given-names>DY</given-names></name><name><surname>Reid</surname><given-names>TR</given-names></name><name><surname>Rose</surname><given-names>SC</given-names></name></person-group><article-title>Oncolytic virotherapy</article-title><source>J Vasc Interv Radiol</source><year>2013</year><volume>24</volume><fpage>1115</fpage><lpage>1122</lpage><pub-id pub-id-type="doi">10.1016/j.jvir.2013.05.040</pub-id><?supplied-pmid 23885911?><pub-id pub-id-type="pmid">23885911</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">FDA Briefing Document Cellular, Tissue, and Gene Therapies Advisory Committee and Oncologic Drugs Advisory Committee Meeting April 29, 2015: BLA 125518 talimogene laherparepvec (Amgen) (2015) <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/UCM444715.pdf">http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAdvisoryCommittee/UCM444715.pdf</ext-link>. Accessed 10 Nov 2015</mixed-citation></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">US Food and Drug Administration (2014) Guidance for industry: design and analysis of shedding studies for virus or bacteria-based gene therapy and oncolytic products. <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM404087.pdf">https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM404087.pdf</ext-link>. Accessed 4 May 2015</mixed-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffner</surname><given-names>B</given-names></name><name><surname>Iodice</surname><given-names>GM</given-names></name><name><surname>Gasal</surname><given-names>E</given-names></name></person-group><article-title>Administration and handling of talimogene laherparepvec: an intralesional oncolytic immunotherapy for melanoma</article-title><source>Oncol Nurs Forum</source><year>2016</year><volume>43</volume><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1188/16.ONF.219-226</pub-id><?supplied-pmid 26906132?><pub-id pub-id-type="pmid">26906132</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirn</surname><given-names>D</given-names></name><name><surname>Martuza</surname><given-names>RL</given-names></name><name><surname>Zwiebel</surname><given-names>J</given-names></name></person-group><article-title>Replication-selective virotherapy for cancer: biological principles, risk management and future directions</article-title><source>Nat Med</source><year>2001</year><volume>7</volume><fpage>781</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1038/89901</pub-id><?supplied-pmid 11433341?><pub-id pub-id-type="pmid">11433341</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>M</given-names></name></person-group><article-title>Clinical development of oncolytic viruses in China</article-title><source>Curr Pharm Biotechnol</source><year>2012</year><volume>13</volume><fpage>1852</fpage><lpage>1857</lpage><pub-id pub-id-type="doi">10.2174/138920112800958760</pub-id><?supplied-pmid 21740357?><pub-id pub-id-type="pmid">21740357</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andtbacka</surname><given-names>RHIA</given-names></name><name><surname>Curti</surname><given-names>BD</given-names></name><name><surname>Kaufman</surname><given-names>H</given-names></name><name><surname>Daniels</surname><given-names>GA</given-names></name><name><surname>Nemunaitis</surname><given-names>JJ</given-names></name><name><surname>Spitler</surname><given-names>LE</given-names></name><name><surname>Hallmeyer</surname><given-names>S</given-names></name><name><surname>Lutzky</surname><given-names>J</given-names></name><name><surname>Schultz</surname><given-names>SM</given-names></name><name><surname>Whitman</surname><given-names>ED</given-names></name><name><surname>Zhou</surname><given-names>K</given-names></name><name><surname>Karpathy</surname><given-names>R</given-names></name><name><surname>Weisberg</surname><given-names>JI</given-names></name><name><surname>Grose</surname><given-names>M</given-names></name><name><surname>Shaffren</surname><given-names>D</given-names></name></person-group><article-title>Final data from CALM: a phase II study of coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><fpage>abstr 9030</fpage><pub-id pub-id-type="doi">10.1200/JCO.2014.58.3377</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andtbacka</surname><given-names>RHIA</given-names></name><name><surname>Ross</surname><given-names>MI</given-names></name><name><surname>Agarwala</surname><given-names>SS</given-names></name><name><surname>Taylor</surname><given-names>MH</given-names></name><name><surname>Vetto</surname><given-names>JT</given-names></name><name><surname>Neves</surname><given-names>RI</given-names></name><name><surname>Daud</surname><given-names>A</given-names></name><name><surname>Khong</surname><given-names>HT</given-names></name><name><surname>Ungerleider</surname><given-names>RS</given-names></name><name><surname>Boran</surname><given-names>A</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Grossmann</surname><given-names>KF</given-names></name></person-group><article-title>Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma</article-title><source>J Clin Oncol</source><year>2016</year><volume>34</volume><fpage>abstr 9543</fpage></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>BL</given-names></name><name><surname>Robinson</surname><given-names>M</given-names></name><name><surname>Han</surname><given-names>ZQ</given-names></name><name><surname>Branston</surname><given-names>RH</given-names></name><name><surname>English</surname><given-names>C</given-names></name><name><surname>Reay</surname><given-names>P</given-names></name><name><surname>McGrath</surname><given-names>Y</given-names></name><name><surname>Thomas</surname><given-names>SK</given-names></name><name><surname>Thornton</surname><given-names>M</given-names></name><name><surname>Bullock</surname><given-names>P</given-names></name><name><surname>Love</surname><given-names>CA</given-names></name><name><surname>Coffin</surname><given-names>RS</given-names></name></person-group><article-title>ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties</article-title><source>Gene Ther</source><year>2003</year><volume>10</volume><fpage>292</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3301885</pub-id><?supplied-pmid 12595888?><pub-id pub-id-type="pmid">12595888</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richard</surname><given-names>C</given-names></name><name><surname>Baro</surname><given-names>J</given-names></name><name><surname>Bello-Fernandez</surname><given-names>C</given-names></name><name><surname>Hermida</surname><given-names>G</given-names></name><name><surname>Calavia</surname><given-names>J</given-names></name><name><surname>Olalla</surname><given-names>I</given-names></name><name><surname>Alsar</surname><given-names>MJ</given-names></name><name><surname>Loyola</surname><given-names>I</given-names></name><name><surname>Cuadrado</surname><given-names>MA</given-names></name><name><surname>Iriondo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) administration after autologous bone marrow transplantation for acute myeloblastic leukemia enhances activated killer cell function and may diminish leukemic relapse</article-title><source>Bone Marrow Transplant</source><year>1995</year><volume>15</volume><fpage>721</fpage><lpage>726</lpage><?supplied-pmid 7670401?><pub-id pub-id-type="pmid">7670401</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Laar</surname><given-names>L</given-names></name><name><surname>Coffer</surname><given-names>PJ</given-names></name><name><surname>Woltman</surname><given-names>AM</given-names></name></person-group><article-title>Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy</article-title><source>Blood</source><year>2012</year><volume>119</volume><fpage>3383</fpage><lpage>3393</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-11-370130</pub-id><?supplied-pmid 22323450?><pub-id pub-id-type="pmid">22323450</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>HL</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>DeRaffele</surname><given-names>G</given-names></name><name><surname>Mitcham</surname><given-names>J</given-names></name><name><surname>Coffin</surname><given-names>RS</given-names></name><name><surname>Kim-Schulze</surname><given-names>S</given-names></name></person-group><article-title>Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma</article-title><source>Ann Surg Oncol</source><year>2010</year><volume>17</volume><fpage>718</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1245/s10434-009-0809-6</pub-id><?supplied-pmid 19915919?><pub-id pub-id-type="pmid">19915919</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andtbacka</surname><given-names>RHI</given-names></name><name><surname>Collichio</surname><given-names>FA</given-names></name><name><surname>Amatruda</surname><given-names>T</given-names></name><name><surname>Senzer</surname><given-names>N</given-names></name><name><surname>Chesney</surname><given-names>J</given-names></name><name><surname>Delman</surname><given-names>K</given-names></name><name><surname>Spitler</surname><given-names>L</given-names></name><name><surname>Puzanov</surname><given-names>I</given-names></name><name><surname>Agarwala</surname><given-names>S</given-names></name><name><surname>Milhem</surname><given-names>M</given-names></name><name><surname>Harrington</surname><given-names>K</given-names></name><name><surname>Middleton</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Shilkrut</surname><given-names>M</given-names></name><name><surname>Coffin</surname><given-names>R</given-names></name><name><surname>Kaufman</surname><given-names>H</given-names></name></person-group><article-title>Final planned overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)</article-title><source>J Immunother Cancer</source><year>2014</year><volume>2</volume><fpage>P263</fpage><pub-id pub-id-type="doi">10.1186/2051-1426-2-S3-P263</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>JM</given-names></name><name><surname>Lamm</surname><given-names>DL</given-names></name><name><surname>Meng</surname><given-names>MV</given-names></name><name><surname>Nemunaitis</surname><given-names>JJ</given-names></name><name><surname>Stephenson</surname><given-names>JJ</given-names></name><name><surname>Arseneau</surname><given-names>JC</given-names></name><name><surname>Aimi</surname><given-names>J</given-names></name><name><surname>Lerner</surname><given-names>S</given-names></name><name><surname>Yeung</surname><given-names>AW</given-names></name><name><surname>Kazarian</surname><given-names>T</given-names></name><name><surname>Maslyar</surname><given-names>DJ</given-names></name><name><surname>McKiernan</surname><given-names>JM</given-names></name></person-group><article-title>A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer</article-title><source>J Urol</source><year>2012</year><volume>188</volume><fpage>2391</fpage><lpage>2397</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2012.07.097</pub-id><?supplied-pmid 23088985?><pub-id pub-id-type="pmid">23088985</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heo</surname><given-names>J</given-names></name><name><surname>Reid</surname><given-names>T</given-names></name><name><surname>Ruo</surname><given-names>L</given-names></name><name><surname>Breitbach</surname><given-names>CJ</given-names></name><name><surname>Rose</surname><given-names>S</given-names></name><name><surname>Bloomston</surname><given-names>M</given-names></name><name><surname>Cho</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>HY</given-names></name><name><surname>Chung</surname><given-names>HC</given-names></name><name><surname>Kim</surname><given-names>CW</given-names></name><name><surname>Burke</surname><given-names>J</given-names></name><name><surname>Lencioni</surname><given-names>R</given-names></name><name><surname>Hickman</surname><given-names>T</given-names></name><name><surname>Moon</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>MK</given-names></name><name><surname>Daneshmand</surname><given-names>M</given-names></name><name><surname>Dubois</surname><given-names>K</given-names></name><name><surname>Longpre</surname><given-names>L</given-names></name><name><surname>Ngo</surname><given-names>M</given-names></name><name><surname>Rooney</surname><given-names>C</given-names></name><name><surname>Bell</surname><given-names>JC</given-names></name><name><surname>Rhee</surname><given-names>BG</given-names></name><name><surname>Patt</surname><given-names>R</given-names></name><name><surname>Hwang</surname><given-names>TH</given-names></name><name><surname>Kirn</surname><given-names>DH</given-names></name></person-group><article-title>Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer</article-title><source>Nat Med</source><year>2013</year><volume>19</volume><fpage>329</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1038/nm.3089</pub-id><?supplied-pmid 23396206?><pub-id pub-id-type="pmid">23396206</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shafren</surname><given-names>DR</given-names></name><name><surname>Au</surname><given-names>GG</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Newcombe</surname><given-names>NG</given-names></name><name><surname>Haley</surname><given-names>ES</given-names></name><name><surname>Beagley</surname><given-names>L</given-names></name><name><surname>Johansson</surname><given-names>ES</given-names></name><name><surname>Hersey</surname><given-names>P</given-names></name><name><surname>Barry</surname><given-names>RD</given-names></name></person-group><article-title>Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus A21</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>53</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-0690-3</pub-id><?supplied-pmid 14734451?><pub-id pub-id-type="pmid">14734451</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>LJ</given-names></name><name><surname>Au</surname><given-names>GG</given-names></name><name><surname>Barry</surname><given-names>RD</given-names></name><name><surname>Shafren</surname><given-names>DR</given-names></name></person-group><article-title>Potent oncolytic activity of human enteroviruses against human prostate cancer</article-title><source>Prostate</source><year>2008</year><volume>68</volume><fpage>577</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1002/pros.20741</pub-id><?supplied-pmid 18288643?><pub-id pub-id-type="pmid">18288643</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skelding</surname><given-names>KA</given-names></name><name><surname>Barry</surname><given-names>RD</given-names></name><name><surname>Shafren</surname><given-names>DR</given-names></name></person-group><article-title>Systemic targeting of metastatic human breast tumor xenografts by coxsackievirus A21</article-title><source>Breast Cancer Res Treat</source><year>2009</year><volume>113</volume><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1007/s10549-008-9899-2</pub-id><?supplied-pmid 18256929?><pub-id pub-id-type="pmid">18256929</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shafren</surname><given-names>D</given-names></name><name><surname>Smithers</surname><given-names>BM</given-names></name><name><surname>Formby</surname><given-names>M</given-names></name></person-group><article-title>A phase I, open-label, cohort study of two doses of coxsackievirus A21 given intratumorally in stage IV melanoma</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><fpage>abstract 8573</fpage><pub-id pub-id-type="doi">10.1200/jco.2011.29.15_suppl.8573</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andtbacka</surname><given-names>RHI</given-names></name><name><surname>Curti</surname><given-names>BD</given-names></name><name><surname>Kaufman</surname><given-names>H</given-names></name><name><surname>Daniels</surname><given-names>GA</given-names></name><name><surname>Nemunaitis</surname><given-names>JJ</given-names></name><name><surname>Spitler</surname><given-names>LE</given-names></name><name><surname>Hallmeyer</surname><given-names>S</given-names></name><name><surname>Lutzky</surname><given-names>J</given-names></name><name><surname>Schultz</surname><given-names>SM</given-names></name><name><surname>Whitman</surname><given-names>ED</given-names></name><name><surname>Zhou</surname><given-names>K</given-names></name><name><surname>Karpathy</surname><given-names>R</given-names></name><name><surname>Weisberg</surname><given-names>JI</given-names></name><name><surname>Grose</surname><given-names>M</given-names></name><name><surname>Shafren</surname><given-names>D</given-names></name></person-group><article-title>Final data from CALM: a phase II study of coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><fpage>abstr 9030</fpage><pub-id pub-id-type="doi">10.1200/JCO.2014.58.3377</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandha</surname><given-names>HS</given-names></name><name><surname>Annels</surname><given-names>NE</given-names></name><name><surname>Simpson</surname><given-names>G</given-names></name><name><surname>Mostafid</surname><given-names>H</given-names></name><name><surname>Harrington</surname><given-names>KJ</given-names></name><name><surname>Melcher</surname><given-names>A</given-names></name><name><surname>Grose</surname><given-names>M</given-names></name><name><surname>Davies</surname><given-names>B</given-names></name><name><surname>Au</surname><given-names>GG</given-names></name><name><surname>Karpathy</surname><given-names>R</given-names></name><name><surname>Shafren</surname><given-names>D</given-names></name></person-group><article-title>Phase I/II canon study: oncolytic immunotherapy for the treatment of nonmuscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21</article-title><source>J Clin Oncol</source><year>2016</year><volume>34</volume><fpage>abstr e16016</fpage></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrington</surname><given-names>KJ</given-names></name><name><surname>Karapanagiotou</surname><given-names>EM</given-names></name><name><surname>Roulstone</surname><given-names>V</given-names></name><name><surname>Twigger</surname><given-names>KR</given-names></name><name><surname>White</surname><given-names>CL</given-names></name><name><surname>Vidal</surname><given-names>L</given-names></name><name><surname>Beirne</surname><given-names>D</given-names></name><name><surname>Prestwich</surname><given-names>R</given-names></name><name><surname>Newbold</surname><given-names>K</given-names></name><name><surname>Ahmed</surname><given-names>M</given-names></name><name><surname>Thway</surname><given-names>K</given-names></name><name><surname>Nutting</surname><given-names>CM</given-names></name><name><surname>Coffey</surname><given-names>M</given-names></name><name><surname>Harris</surname><given-names>D</given-names></name><name><surname>Vile</surname><given-names>RG</given-names></name><name><surname>Pandha</surname><given-names>HS</given-names></name><name><surname>Debono</surname><given-names>JS</given-names></name><name><surname>Melcher</surname><given-names>AA</given-names></name></person-group><article-title>Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers</article-title><source>Clin Cancer Res</source><year>2010</year><volume>16</volume><fpage>3067</fpage><lpage>3077</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-0054</pub-id><?supplied-pmid 20484020?><pub-id pub-id-type="pmid">20484020</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><mixed-citation publication-type="other">Oncolytics Biotech<sup>&#174;</sup> Inc. (2015) Announces Receipt of Orphan Drug Designation from the U.S. FDA for Ovarian Cancer. <ext-link ext-link-type="uri" xlink:href="http://www.oncolyticsbiotech.com/news/oncolytics-biotech-inc-announces-receipt-of-orphan-drug-designation-from-the-u-s-fda-for-ovarian-cancer/">http://www.oncolyticsbiotech.com/news/oncolytics-biotech-inc-announces-receipt-of-orphan-drug-designation-from-the-u-s-fda-for-ovarian-cancer/</ext-link>. Accessed 17 Feb 2017</mixed-citation></ref><ref id="CR74"><label>74.</label><mixed-citation publication-type="other">Oncolytics Biotech<sup>&#174;</sup> Inc. (2014) Announces Additional Data from REO 018 Randomized Study of REOLYSIN<sup>&#174;</sup> in Head and Neck Cancers. <ext-link ext-link-type="uri" xlink:href="http://www.oncolyticsbiotech.com/news/oncolytics-biotech-inc-announces-additional-data-from-reo-018-randomized-study-of-reolysin-in-head-and-neck-cancers/">http://www.oncolyticsbiotech.com/news/oncolytics-biotech-inc-announces-additional-data-from-reo-018-randomized-study-of-reolysin-in-head-and-neck-cancers/</ext-link>. Accessed 17 Feb 2017</mixed-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Puzanov</surname><given-names>I</given-names></name><name><surname>Gajewski</surname><given-names>T</given-names></name><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>VanderWalde</surname><given-names>A</given-names></name><name><surname>Cebon</surname><given-names>J</given-names></name><name><surname>McArthur</surname><given-names>GA</given-names></name><name><surname>Gause</surname><given-names>CK</given-names></name><name><surname>CHen</surname><given-names>L</given-names></name><name><surname>Kaufman</surname><given-names>DR</given-names></name><name><surname>Chou</surname><given-names>J</given-names></name><name><surname>Andtbacka</surname><given-names>RHIA</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name></person-group><article-title>A multicenter, open-label trial of talimogene laherparepvec (T-VEC) plus pembrolizumab vs pembrolizumab monotherapy in previously untreated, unresected, stage IIIB&#8211;IV melanoma</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><fpage>abstr TPS9081</fpage><pub-id pub-id-type="doi">10.1200/JCO.2014.59.5041</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Puzanov</surname><given-names>I</given-names></name><name><surname>Michielin</surname><given-names>O</given-names></name><name><surname>Vanderwalde</surname><given-names>AM</given-names></name><name><surname>Andtbacka</surname><given-names>RHIA</given-names></name><name><surname>Cebon</surname><given-names>JS</given-names></name><name><surname>Fernandez</surname><given-names>E</given-names></name><name><surname>Malvehy</surname><given-names>J</given-names></name><name><surname>Olszanski</surname><given-names>AJ</given-names></name><name><surname>Gajewski</surname><given-names>T</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>Kuznetsova</surname><given-names>O</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Diede</surname><given-names>SJ</given-names></name><name><surname>Chou</surname><given-names>J</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name></person-group><article-title>A phase 1/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab for unresected, stage IIIBIV melanoma (MASTERKEY265)</article-title><source>J Clin Oncol</source><year>2016</year><volume>34</volume><fpage>9598</fpage><pub-id pub-id-type="doi">10.1200/JCO.2015.62.9345</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><mixed-citation publication-type="other">Long GV, Dummer R, Ribas A et al Primary analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec and pembrolizumab for unresectable stage IIIB&#8211;IV melanoma. In: 12th International Congress of the Society for Melanoma Research, San Francisco, CA, November 18&#8211;21</mixed-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>GV</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Puzanov</surname><given-names>I</given-names></name><name><surname>VanderWalde</surname><given-names>A</given-names></name><name><surname>Andtbacka</surname><given-names>RHIA</given-names></name><name><surname>Michielin</surname><given-names>O</given-names></name><name><surname>Olszanski</surname><given-names>AJ</given-names></name><name><surname>Malvehy</surname><given-names>J</given-names></name><name><surname>Cebon</surname><given-names>JS</given-names></name><name><surname>Fernandez</surname><given-names>E</given-names></name><name><surname>Kirkwood</surname><given-names>JM</given-names></name><name><surname>Gajewski</surname><given-names>T</given-names></name><name><surname>Gause</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Gorski</surname><given-names>K</given-names></name><name><surname>Anderson</surname><given-names>A</given-names></name><name><surname>Kaufman</surname><given-names>DR</given-names></name><name><surname>Chou</surname><given-names>J</given-names></name><name><surname>Hodi</surname><given-names>FS</given-names></name></person-group><article-title>Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB&#8211;IV melanoma</article-title><source>J Clin Oncol</source><year>2016</year><volume>34</volume><fpage>abstr 9568</fpage><pub-id pub-id-type="doi">10.1200/JCO.2015.62.9345</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandha</surname><given-names>HS</given-names></name><name><surname>Harrington</surname><given-names>KJ</given-names></name><name><surname>Ralph</surname><given-names>C</given-names></name><name><surname>Melcher</surname><given-names>A</given-names></name><name><surname>Mansfield</surname><given-names>D</given-names></name><name><surname>Grose</surname><given-names>M</given-names></name><name><surname>Davies</surname><given-names>B</given-names></name><name><surname>Karpathy</surname><given-names>R</given-names></name><name><surname>Shafren</surname><given-names>D</given-names></name></person-group><article-title>Phase I STORM study (KEYNOTE 200): intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients</article-title><source>J Clin Oncol</source><year>2016</year><volume>34</volume><fpage>abstr TPS3108</fpage><pub-id pub-id-type="doi">10.1200/JCO.2016.67.8987</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abou-Alfa</surname><given-names>GK</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Chao</surname><given-names>Y</given-names></name><name><surname>Brown</surname><given-names>KT</given-names></name><name><surname>Heo</surname><given-names>J</given-names></name><name><surname>Borard</surname><given-names>MJ</given-names></name><name><surname>Luca</surname><given-names>A</given-names></name><name><surname>Pelusio</surname><given-names>A</given-names></name><name><surname>Agathon</surname><given-names>D</given-names></name><name><surname>Lusky</surname><given-names>M</given-names></name><name><surname>Breitbach</surname><given-names>C</given-names></name><name><surname>Burke</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name></person-group><article-title>PHOCUS: a phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy</article-title><source>J Clin Oncol</source><year>2016</year><volume>34</volume><fpage>abstr TPS4146</fpage><pub-id pub-id-type="doi">10.1200/jco.2016.34.4_suppl.192</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freytag</surname><given-names>SO</given-names></name><name><surname>Stricker</surname><given-names>H</given-names></name><name><surname>Pegg</surname><given-names>J</given-names></name><name><surname>Paielli</surname><given-names>D</given-names></name><name><surname>Pradhan</surname><given-names>DG</given-names></name><name><surname>Peabody</surname><given-names>J</given-names></name><name><surname>DePeralta-Venturina</surname><given-names>M</given-names></name><name><surname>Xia</surname><given-names>X</given-names></name><name><surname>Brown</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name></person-group><article-title>Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>7497</fpage><lpage>7506</lpage><?supplied-pmid 14612551?><pub-id pub-id-type="pmid">14612551</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>T</given-names></name><name><surname>Galanis</surname><given-names>E</given-names></name><name><surname>Abbruzzese</surname><given-names>J</given-names></name><name><surname>Sze</surname><given-names>D</given-names></name><name><surname>Wein</surname><given-names>LM</given-names></name><name><surname>Andrews</surname><given-names>J</given-names></name><name><surname>Randlev</surname><given-names>B</given-names></name><name><surname>Heise</surname><given-names>C</given-names></name><name><surname>Uprichard</surname><given-names>M</given-names></name><name><surname>Hatfield</surname><given-names>M</given-names></name><name><surname>Rome</surname><given-names>L</given-names></name><name><surname>Rubin</surname><given-names>J</given-names></name><name><surname>Kirn</surname><given-names>D</given-names></name></person-group><article-title>Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>6070</fpage><lpage>6079</lpage><?supplied-pmid 12414631?><pub-id pub-id-type="pmid">12414631</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khuri</surname><given-names>FR</given-names></name><name><surname>Nemunaitis</surname><given-names>J</given-names></name><name><surname>Ganly</surname><given-names>I</given-names></name><name><surname>Arseneau</surname><given-names>J</given-names></name><name><surname>Tannock</surname><given-names>IF</given-names></name><name><surname>Romel</surname><given-names>L</given-names></name><name><surname>Gore</surname><given-names>M</given-names></name><name><surname>Ironside</surname><given-names>J</given-names></name><name><surname>MacDougall</surname><given-names>RH</given-names></name><name><surname>Heise</surname><given-names>C</given-names></name><name><surname>Randlev</surname><given-names>B</given-names></name><name><surname>Gillenwater</surname><given-names>AM</given-names></name><name><surname>Bruso</surname><given-names>P</given-names></name><name><surname>Kaye</surname><given-names>SB</given-names></name><name><surname>Hong</surname><given-names>WK</given-names></name><name><surname>Kirn</surname><given-names>DH</given-names></name></person-group><article-title>A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer</article-title><source>Nat Med</source><year>2000</year><volume>6</volume><fpage>879</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1038/78638</pub-id><?supplied-pmid 10932224?><pub-id pub-id-type="pmid">10932224</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galanis</surname><given-names>E</given-names></name><name><surname>Okuno</surname><given-names>SH</given-names></name><name><surname>Nascimento</surname><given-names>AG</given-names></name><name><surname>Lewis</surname><given-names>BD</given-names></name><name><surname>Lee</surname><given-names>RA</given-names></name><name><surname>Oliveira</surname><given-names>AM</given-names></name><name><surname>Sloan</surname><given-names>JA</given-names></name><name><surname>Atherton</surname><given-names>P</given-names></name><name><surname>Edmonson</surname><given-names>JH</given-names></name><name><surname>Erlichman</surname><given-names>C</given-names></name><name><surname>Randlev</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Freeman</surname><given-names>S</given-names></name><name><surname>Rubin</surname><given-names>J</given-names></name></person-group><article-title>Phase I&#8211;II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas</article-title><source>Gene Ther</source><year>2005</year><volume>12</volume><fpage>437</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3302436</pub-id><?supplied-pmid 15647767?><pub-id pub-id-type="pmid">15647767</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>T</given-names></name><name><surname>Galanis</surname><given-names>E</given-names></name><name><surname>Abbruzzese</surname><given-names>J</given-names></name><name><surname>Sze</surname><given-names>D</given-names></name><name><surname>Andrews</surname><given-names>J</given-names></name><name><surname>Romel</surname><given-names>L</given-names></name><name><surname>Hatfield</surname><given-names>M</given-names></name><name><surname>Rubin</surname><given-names>J</given-names></name><name><surname>Kirn</surname><given-names>D</given-names></name></person-group><article-title>Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial</article-title><source>Gene Ther</source><year>2001</year><volume>8</volume><fpage>1618</fpage><lpage>1626</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3301512</pub-id><?supplied-pmid 11895000?><pub-id pub-id-type="pmid">11895000</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hecht</surname><given-names>JR</given-names></name><name><surname>Bedford</surname><given-names>R</given-names></name><name><surname>Abbruzzese</surname><given-names>JL</given-names></name><name><surname>Lahoti</surname><given-names>S</given-names></name><name><surname>Reid</surname><given-names>TR</given-names></name><name><surname>Soetikno</surname><given-names>RM</given-names></name><name><surname>Kirn</surname><given-names>DH</given-names></name><name><surname>Freeman</surname><given-names>SM</given-names></name></person-group><article-title>A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><fpage>555</fpage><lpage>561</lpage><?supplied-pmid 12576418?><pub-id pub-id-type="pmid">12576418</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nemunaitis</surname><given-names>J</given-names></name><name><surname>Cunningham</surname><given-names>C</given-names></name><name><surname>Tong</surname><given-names>A</given-names></name><name><surname>Post</surname><given-names>L</given-names></name><name><surname>Netto</surname><given-names>G</given-names></name><name><surname>Paulson</surname><given-names>AS</given-names></name><name><surname>Rich</surname><given-names>D</given-names></name><name><surname>Blackburn</surname><given-names>A</given-names></name><name><surname>Sands</surname><given-names>B</given-names></name><name><surname>Gibson</surname><given-names>B</given-names></name><name><surname>Randlev</surname><given-names>B</given-names></name><name><surname>Freeman</surname><given-names>S</given-names></name></person-group><article-title>Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients</article-title><source>Cancer Gene Ther</source><year>2003</year><volume>10</volume><fpage>341</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1038/sj.cgt.7700585</pub-id><?supplied-pmid 12719704?><pub-id pub-id-type="pmid">12719704</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranki</surname><given-names>T</given-names></name><name><surname>Pesonen</surname><given-names>S</given-names></name><name><surname>Hemminki</surname><given-names>A</given-names></name><name><surname>Partanen</surname><given-names>K</given-names></name><name><surname>Kairemo</surname><given-names>K</given-names></name><name><surname>Alanko</surname><given-names>T</given-names></name><name><surname>Lundin</surname><given-names>J</given-names></name><name><surname>Linder</surname><given-names>N</given-names></name><name><surname>Turkki</surname><given-names>R</given-names></name><name><surname>Ristimaki</surname><given-names>A</given-names></name><name><surname>Jager</surname><given-names>E</given-names></name><name><surname>Karbach</surname><given-names>J</given-names></name><name><surname>Wahle</surname><given-names>C</given-names></name><name><surname>Kankainen</surname><given-names>M</given-names></name><name><surname>Backman</surname><given-names>C</given-names></name><name><surname>von Euler</surname><given-names>M</given-names></name><name><surname>Haavisto</surname><given-names>E</given-names></name><name><surname>Hakonen</surname><given-names>T</given-names></name><name><surname>Heiskanen</surname><given-names>R</given-names></name><name><surname>Jaderberg</surname><given-names>M</given-names></name><name><surname>Juhila</surname><given-names>J</given-names></name><name><surname>Priha</surname><given-names>P</given-names></name><name><surname>Suoranta</surname><given-names>L</given-names></name><name><surname>Vassilev</surname><given-names>L</given-names></name><name><surname>Vuolanto</surname><given-names>A</given-names></name><name><surname>Joensuu</surname><given-names>T</given-names></name></person-group><article-title>Phase I study with ONCOS-102 for the treatment of solid tumors&#8212;an evaluation of clinical response and exploratory analyses of immune markers</article-title><source>J Immunother Cancer</source><year>2016</year><volume>4</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1186/s40425-016-0121-5</pub-id><?supplied-pmid 26981247?><pub-id pub-id-type="pmid">26981247</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dias</surname><given-names>JD</given-names></name><name><surname>Hemminki</surname><given-names>O</given-names></name><name><surname>Diaconu</surname><given-names>I</given-names></name><name><surname>Hirvinen</surname><given-names>M</given-names></name><name><surname>Bonetti</surname><given-names>A</given-names></name><name><surname>Guse</surname><given-names>K</given-names></name><name><surname>Escutenaire</surname><given-names>S</given-names></name><name><surname>Kanerva</surname><given-names>A</given-names></name><name><surname>Pesonen</surname><given-names>S</given-names></name><name><surname>Loskog</surname><given-names>A</given-names></name><name><surname>Cerullo</surname><given-names>V</given-names></name><name><surname>Hemminki</surname><given-names>A</given-names></name></person-group><article-title>Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4</article-title><source>Gene Ther</source><year>2012</year><volume>19</volume><fpage>988</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.1038/gt.2011.176</pub-id><?supplied-pmid 22071969?><pub-id pub-id-type="pmid">22071969</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pol</surname><given-names>JG</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Bridle</surname><given-names>BW</given-names></name><name><surname>Stephenson</surname><given-names>KB</given-names></name><name><surname>Resseguier</surname><given-names>J</given-names></name><name><surname>Hanson</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Kazdhan</surname><given-names>N</given-names></name><name><surname>Bramson</surname><given-names>JL</given-names></name><name><surname>Stojdl</surname><given-names>DF</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Lichty</surname><given-names>BD</given-names></name></person-group><article-title>Maraba virus as a potent oncolytic vaccine vector</article-title><source>Mol Ther</source><year>2014</year><volume>22</volume><fpage>420</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1038/mt.2013.249</pub-id><?supplied-pmid 24322333?><pub-id pub-id-type="pmid">24322333</pub-id></element-citation></ref></ref-list></back></article>